\

SYSTEMATIC ANALYSIS OF THE TIME COURSE TO DEVELOP THERAPEUTIC INTERVENTIONS FOR COVID-19

Binh T. Ngo, M.D.[1,2,*]
binhngo@medmail.usc.edu

Paul Marik, M.D., F.C.C.P., F.C.C.M.
Eastern Virginia Medical School|
Department of Internal Medicine|
Chief, Pulmonary and Critical Care Medicine|
825 Fairfax Ave, Rm 575, Norfolk, VA 23507|
marikpe@evms.edu

Pierre Kory, M.D., M.P.A
Pulmonary and Critical Care Medicine
Aurora St. Luke's Medical Center
Milwaukee, Wisconsin .
pierrekory@icloud.com

Leland Shapiro, M.D.
Rocky Mountain Regional Veterans Affairs Medical Center in Aurora, CO and
University of Colorado Anschutz Medical Campus in Aurora, CO
Supported by The Emily Foundation in Boston, MA
lelandshapiro@cuanschutz.edu

Raphael Thomadsen, P.h.D.
Washington University in St. Louis
thomadsen@wustl.edu

Jose Iglesias, D.O., F.A.S.N.
Jersey Shore University Medical Center, Neptune NJ, Hackensack Meridian School of Medicine at Seton Hall
Jiglesias23@gmail.com

Stephen Ditmore, B.A.
Parkchester Times
stephen.ditmore@gmail.com

Marc Rendell, M.D.[2,*]
The Rose Salter Medical Research Foundation
Newport Coast, CA 92657
rendell@asndi.com

Joseph Varon, MD, FACP, FCCP, FCCM, FRSM
United Memorial Medical Center
University of Texas School of Medicine
Houston, Texas, USA
joevaron@roamer.net

Michael Dubé, M.D.[1]
mdube@med.usc.edu

Neha Nanda, MD[1]
Neha.nanda@med.usc.edu

Gino In, M.D., M.P.H.[1]
Gino.In@med.usc.edu

Daniel Arkfeld,M.D. 1
arkfeld@med.usc.edu

Preet Chaudhary, M.D.[1]
Preet.chaudhary@med.usc.edu

Vito M. Campese, M.D. [1]
campese@med.usc.edu

Diana L. Hanna, M.D. [1]
Diana.Hanna@medmail.usc.edu

David E. Sawcer, M.D. Ph.D.[1]
David.sawcer@medmail.usc.edu

Glenn Ehresmann, M.D.[1]
Glenn.ehresmann@medmail.usc.edu

David Peng, M.D., M.P.H.[1]
David.Peng@medmail.usc.edu

Miroslaw Smogorewski, M.D.[1]
smogorze@med.usc.edu

April Armstrong, M.D., M.P.H.[1]
April.armstrong@medmail.usc.edu

Rajkumar Dasgupta, M.D.[1]
"Dasgupta, Rajkumar" <rdasgupt@med.usc.edu>

Fred Sattler, M.D.[1]
fsattler@usc.edu

Cristina Mussini, MD
University of Modena and Reggio Emilia in Italy
Cristina.mussini@unimore.it

Oriol Mitja, Ph.D.
Hospital Universitari Germans Trias i Pujol
Badalona, Spain
omitja@flsida.org

Vicente Soriano, MD PhD
UNIR Health Sciences School & Medical Center
C/ Almansa 101
Madrid 28040, Spain
Vicente.soriano@unir.net

Nicolas Peschanski, M.D., Ph.D
UniversityHospital of Rennes
Rennes, France
nicolas.peschanski@chu-rennes.fr

Gilles Hayem, M.D.
Hôpital Paris Saint-. Joseph, 75014
Paris, France.
ghayem@ghpsj.fr

Marco Confalonieri, M.D.
Azienda Ospedaliero-Universitaria di Trieste
Trieste, Italia

marco.confalonieri@asugi.sanita.fvg.it

Maria Carmela Piccirillo, M.D.
Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale
Napoli, Italia
m.piccirillo@istitutotumori.na.it

Antonio Lobo-Ferreira, M.D. , Ph.D.
Unidade de Investigação Cardiovascular (UniC), Faculdade de Medicina
da Universidade do Porto, Centro Hospitalar Universitário de São João,
Porto, and Hospital Rainha Santa Isabel, Marco de Canaveses, Portugal
Aloboferreira@gmail.com

Iraldo Bello Rivero M.Sc., Ph.D.
Department of Clinical Investigations
Center for Genetic Engineering and Biotechnology,
Ave 31 e/ 158 and 190. Cubanacan, Playa, 10600
, Havana, Cuba.
iraldo.bello@cigb.edu.cu

Eivind H. Vinjevoll, M.D.
Volda Hospital HMR, Norway.
Eivind.vinjevoll@gmail.com

Ivan FN Hung, MBChB, MD, MRCP, FRCP[*3]
Li Ka Shing Faculty of Medicine
University of Hong Kong
Ivanhung@hku.hk

1 From the Keck Medical School of USC
2 From the Rose Salter Medical Research Foundation
3 Senior author
* Corresponding author

ABSTRACT

BACKGROUND. The spread of COVID-19 from Wuhan China, has been alarmingly rapid. Epidemiologic techniques succeeded in containing the disease in China, but efforts have not been as successful in the rest of the World, particularly the United States, where there have been 21,026,758 confirmed cases of COVID-19, including 755,786 deaths as of August 15, 2020. Projections are for continued new infections and deaths if no effective therapeutic interventions can be initiated over the next several months. We performed a systematic review to determine the potential time course for development of treatments and vaccines, focusing on availability now and continuing in the last half of 2020.

METHODS. Clinical Trials: We reviewed up-to-date information from several sources to identify potential treatments for COVID-19: The Reagan-Udall Expanded Access Navigator COVID-19 Treatment Hub was used to track the efforts of companies to develop agents. We focused on trials completed or recruiting for patients as of April 1, 2020 on identified agents, reasoning that the timeline to provide treatments by the end of 2020 would require completion of enrollment within the next 3 months. We used several different sources: (A) covid-trials.org, then validated results on (B) clinicaltrials.gov and the (C) World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP). We excluded studies which were clearly observational, with no randomization, control, or comparison group. We further set a cutoff of 100 for numbers of subjects,

since smaller trial size could lack statistical power to establish superiority of the intervention over the control.

Publications: We searched for published trial results on pubmed.gov and on medRxiv, the preprint server, and used a targeted Google™ search to find announcements of unpublished trial results

RESULTS. Published Data: As of August 15, 2020 we found 63 publications reporting findings in human studies on 13 classes of drugs and on 5 vaccines. There were only 24 randomized placebo or active control studies; the rest were retrospective observational. Only seven publications dealt with outpatient care, the rest all in hospitalized patients.

Clinical Trials: As of our cutoff date of April 1, 2020, we found 409 trials meeting our minimum requirement of 100 subjects. The WHO Solidarity megatrial for hospitalized patients was launched in over 100 countries, actively comparing hydroxychloroquine (HCQ), lopanovir/ritonavir (LPV/r) alone and in combination with interferon beta-1, and remdesivir. The LPV/r alone and HCQ arms have already been discontinued. In addition, we found 46 trials of HCQ, 11 trials of LPV/r and 8 trials of interferons. There were 18 ongoing trials of antiviral agents, 24 immune modulator studies, 9 vaccine trials, and 62 studies of other agents. We excluded a large number of trials of traditional Chinese medications, reasoning that there was insufficient clinical experience with these agents outside China. Forty four trials were hoping to complete enrollment by the end of the second quarter of 2020. Of these, only 9 were conducted on outpatients. A few vaccine trials are hoping to complete Phase 3 enrollment by the end of the third quarter 2020, but a prolonged follow-up of patients will likely be required.

Available Treatments. At this time, only remdesivir has emerged as a treatment, solely for hospitalized patients. There is also support for glucocorticoid treatment of the COVID-19 respiratory distress syndrome in the ICU. No treatments or prophylaxis are offered for outpatients.

CONCLUSION. COVID-19 is propagated primarily by infected ambulatory individuals. There have been no options brought forward for prevention and non-hospital treatment with only a few randomized, controlled outpatient studies expected to yield results in time to impact on the continuing pandemic by the end of 2020. It will be necessary for public health authorities to make hard decisions, with limited data, to prevent the continued spread of the disease. The choices will be hardest when dealing with possible early release of safe and effective vaccines which would, of course, be of greatest benefit to the World's population.

Keywords: Coronavirus, COVID-19, SARS-Cov-2, remdesivir, hydroxychloroquine, favipiravir

* corresponding authors. email: Binh.ngo@med.usc.edu; Ivanhung@hku.hk;

INTRODUCTION

The coronavirus SARS-Cov-2 pandemic spread through the World with extraordinary speed from its origin in December 2019 in Wuhan, China. As of August 15, 2020, there have been 21,026,758 confirmed cases of COVID-19, including 755,786 deaths worldwide affecting 220 countries and territories (1). This viral and multisystemic illness produces mild or no symptoms in about 80% of infected individuals, however, in about 20% can manifest as pneumonia, which may progress to acute respiratory failure requiring assisted mechanical ventilation in up to 5% of patients (2). The infection fatality ratio is difficult to determine due to a high percentage of undiagnosed cases (3). A calculation based on the outbreak among the passengers and crew of the cruise ship Diamond Princess, essentially a captive population, suggested a case fatality ratio of 1.3% (4). The mortality is highest in the elderly and in those with chronic disease.

Symptomatic COVID-19 exhibits a characteristic sequence of events related to the primary viral attack, manifesting as an influenza-like illness with cough, fever, myalgias and fatigue, and then, subsequently, an overlapping hyperinflammatory reaction (See Figure 1) (5). In patients with severe disease, within seven to 10 days of onset of symptoms, bilateral multiple lobar and subsegmental areas of consolidation are typically seen on chest computed tomography (CT) (6). Pneumonia may rapidly progress to acute respiratory failure with elevated cytokines suggesting an immune reaction as probable cause (7,8). Additionally, a coagulopathy develops and can affect the lungs and other organs, including

triggering cerebrovascular accidents (9,10). Recently, a new syndrome of pediatric multisystem inflammatory disorder has surfaced among children, previously thought minimally susceptible to severe COVID-19 disease. This is apparently a delayed autoimmune condition which can occur a month or more after the initial SARS-Cov-2 infection, and can be fatal (11).

In mainland China, vigorous efforts to contain the spread of COVID-19 by home isolation, closure of business activity, travel bans, and tracking and control of contacts succeeded. As of August 15, China has had 89,695confirmed cases with 4,708 deaths, but the number of new cases has declined to very low levels since April (1). Similar measures contained the epidemic in Korea, Taiwan and in New Zealand (12). In Hong Kong, one of the most densely populated areas in the world, universal masking, immediate hospitalization and early antiviral treatment for all confirmed cases have minimized the number of confirmed COVID-19 cases to 4200 in a 7.5 million population with less than 3% requiring ICU care, and 60 fatalities (13,14). However, the disease has not been similarly controlled in the rest of the World, particularly the United States (USA) where, despite only a fifth of the population of China, there were 5,203,206 confirmed cases of COVID-19 with 165,995 deaths as of August 15, 2020 (1). In the USA, as in China, the response to the pandemic was through reduction of person-to-person contact by social distancing. Beginning in early March, schools and businesses were closed along with recreation areas, parks, and beaches. Social gatherings and meetings ended. These efforts blunted the spread of the disease, but not with the results achieved in China. Due to economic pressures, epidemiologic containment was relaxed resulting in a significant surge surpassing the original April peak. Kissler and collaborators created a series of simulations based on known data on the transmissibility of other less-threatening betacoronaviruses, cross-immunity with those viruses,

seasonal variations, and the impact of social distancing (15). Their optimal predicted scenario was for indefinite social distancing, which even early on, has triggered massive unemployment and crippled the economy of the USA. These investigators stated that medications or vaccines for COVID-19 would reduce the need for reliance on epidemiologic containment.

Facing the growing crisis in early January, Chinese health authorities began treating patients empirically with agents with demonstrated *in vitro* antiviral activity against coronaviruses and those used during the SARS 2003, the H1N1 influenza of 2009 and MERS 2015 outbreaks in Asia (16). The medications used included the antimalarial drugs hydroxychloroquine (HCQ) and chloroquine, the human immunodeficiency virus (HIV) protease inhibitor lopanovir-ritanovir (LPV/r), the Russian antiviral umifenovir, and traditional Chinese medical approaches (17). Subsequently, the antimalarials were widely used to treat COVID-19 throughout the world, despite cautions from numerous regulatory bodies. The scientific basis for their use was *in vitro* evidence of an effect on blocking viral endosomal penetration, as well as a known suppressive benefit on undesirable autoimmune effects (18). Clinical studies have shown conflicting results.

Multiple vaccines are in clinical trials to assess safety and effectiveness, but these studies are unlikely to complete Phase III testing and proceed to mass vaccination until early 2021. In view of the continuing daily increase in new cases and deaths, our goal was to assess the options we have now for release of pharmacologic agents to treat and to prevent COVID-19 while awaiting widespread immunization.

METHODS

CLINICAL TRIALS: We reviewed up-to-date information from several sources to identify potential treatments for COVID-19: The Reagan-Udall Expanded Access Navigator COVID-19 Treatment Hub was used to track the efforts of companies to develop therapeutic interventions. We searched for investigational trials which had completed or had begun active recruitment as of April 1, 2020, reasoning that the timeline to implement treatments in the second half of 2020 would require completion by July 1. We used (A) covid-trials.org, a registry to collate all trials in real time with data pulled from the International Clinical Trials Registry Platform and all major national registries (19).We cross validated information on (B) clinicaltrials.gov the registry of clinical trials information maintained by the United States National Library of Medicine. We further cross referenced the trials on (C) the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP).

We excluded studies which were clearly observational for treatment purposes, with no randomization, control or comparison group. We further set a cutoff of 100 for numbers of subjects since smaller trial size could lack statistical power to enable regulatory approval. For each trial selected, we documented the setting of patient contact, either hospital or outpatient, the type of control procedure, the date the trial was initially registered, and the proposed date of completion of enrollment.

PUBLISHED TRIAL RESULTS: Our search was carried on the week of August 10, 2020. We identified all publications on pubmed.gov to find peer reviewed articles and medRxiv to find preprint

reports. We further carried out daily Google™ searches on each potential treatment to find preliminary reports, typically presented as press releases, reviewed by a journalist.

VIRTUAL DISCUSSIONS AMONG CO-AUTHORS: We used the preprint server medRxiv to post a systematic analysis of the development of therapeutic interventions for COVID-19 in order to alllow widespread input and stimulate discussion of the manuscript (20). Successive versions were reposted periodically beginning in late May, 2020 and continuing to date.

RESULTS

REVIEW OF CURRENT TRIALS: As of our cutoff date of April 1, we identified 781 trials worldwide meeting our review criteria. Approximately half the trials were registered in mainland China, and 103 trials were registered in the U.S.A.(See TABLE 1). There were 553 trials in the recruitment process or completed (SUPPLEMENTARY TABLE 1). We found 409 trials meeting the minimum requirement of 100 subjects which were recruited or completed as of April 1. The WHO organized a megatrial, appropriately named Solidarity, to assess four separate treatment options: Remdesivir, an intravenously administered inhibitor of RNA polymerase; LPV/R; LPV/R plua Interferon beta-1a; and HCQ or Chloroquine (21). Critical study information is collected only at randomization and when the patient is discharged or dies: which study drugs were given(and for how many days); whether ventilation or intensive care was received, date of discharge, or date and cause of death while still in hospital. Data is transmitted centrally to the trial database. Completion of enrollment is estimated in the first quarter of 2021. Recently, the antimalarial and LPV/R drug arms of the Solidarity study were terminated after review suggested no benefit in hospitalized patients.

OTHER TRIALS WITH THE SOLIDARITY AGENTS: In addition to and independent from the Solidarity trial, we found 46 ongoing trials of HCQ, 11 trials of LPV/r and 8 trials of interferons (See TABLE 2). There were 21 HCQ trials focused solely on hospitalized patients. Ten HCQ trials focused on prevention of the disease. There were seven HCQ trials conducted on ambulatory patients with diagnosed mild disease. The HCQ and LPV/R arms of the RECOVERY trial in hospitalized patients in the United Kingdom have ended after preliminary data showed no change in mortality. The NIH has halted its HCQ studies.

Two prevention trials with LPV/r are currently enrolling, with earliest enrollment completion in the second quarter of 2020 for one and the third quarter for the other. There is one outpatient active comparison trial with HCQ with proposed enrollment end in the second quarter of 2020. There is one large interferon prevention trial scheduled to complete enrollment in the second quarter of 2020.

ANTIVIRAL AGENTS: SARS-Cov-2 attacks cells by binding of the spike protein to the host cell ACE2 receptor. A specific serine protease TMPRSS2 then activates membrane fusion allowing viral RNA to enter the cell to be replicated with release of multiple virions. Numerous antiviral agents are now in active trials (See TABLE 3). In addition to remdesivir, and favipiravir (FVP), an oral inhibitor of the polymerase, trials are ongoing with umifenovir, a membrane lipid fusion inhibitor with broad antiviral properties and with camostat which is a potent serine protease inhibitor (22,23). A very large, multicenter, prevention trial for hospital workers exposed to COVID-19 in Spain, involves 4000 subjects who will be randomized to emicitrabine/tenofovir, an HIV agent, or to HCQ or to placebo. The trial has planned to meet its enrollment goal by the beginning of the third quarter of 2020.

IMMUNE MODULATORS: Many trials are focusing on tocilizumab and anakinra, as well as other agents currently approved for treatment for rheumatoid arthritis and other autoimmune conditions to suppress the cytokine storm of COVID-19 (See TABLE 4). These trials are all directed at severely ill COVID-19 inpatients. There is a large multicenter, placebo-controlled trial of colchicine in non-severely ill outpatients scheduled to enroll 6000 individuals by end of the third quarter of 2020.

OTHER STUDIES (SUPPLEMENTARY TABLE 2):

CONVALESCENT PLASMA: Several studies of intravenous globulin as well as intravenous hyperimmune globulin plan completion of enrollment in the third quarter of 2020.

STEM CELLS: Several trials of mesenchymal stem cells are currently recruiting with one study planning completion of enrollment by the end of the second quarter of 2020.

RENIN ANGIOTENSIN SYSTEM: Angiotensin-converting enzyme 2 is the monocarboxypeptidase highly expressed in alveolar epithelial cells and endothelial cells.. This receptor has been identified as the binding site for the SARSCoV-2 virus on epithelial cell for entry, speculating interest that ACE inhibitors or angiotensin receptor blockers might block viral access. There are a number of trials either adding the agents or withdrawing them. One small trial of losartan has been fully enrolled but no results have been posted as yet.

PULMONARY AND RESPIRATORY INTERVENTIONS: These studies are of great interest in managing respiratory failure in COVID-19. There are many ongoing studies of mechanical and extracorporeal oxygenation. Most of the studies did not meet the criterion of 100 subjects or more (SUPPLEMENTARY TABLE 1). There was one ongoing study of hyperbaric oxygenation not due to complete enrollment until the second quarter of 2021. Pirfenidone is an agent approved to treat pulmonary fibrosis, and one study is planning completion of enrollment by the end of the second quarter of 2020.

SUPPLEMENTS: The suggestion that zinc may be a beneficial agent together with HCQ in COVID-19 has generated interest, but there is only one study underway, not including HCQ.

GLUCOCORTICOIDS: Given the potential benefit of glucocorticoids during the hyperinfllammatory phase of COVID-19, a number of studies are trying to determine the best timing to begin steroid use without impairing the response to viremia.

ANTICOAGULANTS: Several studies are focusing on prophylaxis for the COVID-19 hypercoagulable state. There are no current studies of the new direct oral anticoagulants.

TRADITIONAL CHINESE MEDICATIONS: There were 48 such studies. We did not include them in our search for agents which could be made available in the next 6 months for two reasons. First, these medications are not familiar to clinicians in the rest of the World. Second, the success of epidemiologic containment in China has made it unlikely that many projected trials would achieve enrollment.

VACCINES: The WHO has identified 110 programs to develop a SARS-Cov-2 vaccine. Of these, 12 have reached initial human trials (See TABLE 5). Optimistic observers have suggested that a vaccine could be available by the beginning of 2021. A bold suggestion has been made to allow emergency authorization of favorable vaccine candidates by the fall. An additional approach has been suggested to attempt to stimulate non-specific immunity prior to availability of a COVID-19 vaccine using oral polio vaccine or BCG vaccination (24). There are two large prevention trials underway in the Netherlands and Australia using BCG vaccine in health care workers. These trials plan conclusion of enrollment, but not until the fourth quarter of 2020.

PUBLISHED RESULTS ON COVID-19 TRIALS: As of August 10, 2020 we found 63 publications reporting findings in human studies on 13 classes of drugs, and on 5 vaccines (See

TABLE 6). There were only 23 randomized placebo or active controlled studies. The rest were retrospective observational analyses. Only seven publications dealt with outpatient care, the rest all in hospitalized patients.

In the group of antiviral agents, the largest published randomized, controlled trials were with remdesivir. The first multicenter trial conducted at ten hospitals in Hubei, China was halted in April due to lack of recruitment after 237 patients enrolled (25). Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1.23 [95% CI 0.87–1.75]) and no mortality benefit . The largest trial of remdesivir, in 1063 moderate to severely ill patients, was a double blind, randomized placebo controlled study (RCTPLAC) carried out by the National Institute of Arthritis and Infectious Disease (NIAID) (27). The patients who received remdesivir had a median recovery time of 11 days (95% confidence interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) for those who received placebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P<0.001). The Kaplan-Meier estimates of mortality by 14 days after randomization were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04). There was no data documenting the rate of viral clearance. On the basis of this trial, the Food and Drug Administration (FDA) issued an emergency authorization for use of remdesivir for severely ill COVID hospitalized patients. Subsequently, a report was published showing that in 397 hospitalized patients with moderate to severe disease, there was no difference in outcome comparing patients who received a 5 day course of remdesivir versus a 10 day course (28). The analysis was complicated by an imbalance in clinical severity; the patients randomized to 10 days of treatment had significantly more severe disease than

those in the 5 day group. The 14 day mortality in the 5 day group was 8% versus 11% in the 10 day group. In this study, there was no data on viral clearance.

There were two randomized, active control clinical trials in China of favipiravir (FVP) (29,30). In a study of 35 patients receiving FVP, compared to 45 patients receiving LPV/R plus inhaled interferon alpha, a shorter viral clearance time was found for the FVP arm (median (interquartile range, IQR), 4 (2.5–9) days versus 11 (8–13) days, $p < 0.001$) (29). The FVP arm also showed significant improvement in chest imaging compared with the control arm, with an improvement rate of 91.4% versus 62.2% ($p = 0.004$). In a larger Chinese trial comparing 116 patients on FVP to 120 on umifenovir, the 7 day clinical recovery rate was 55.9% for the umifenovir group and 71% in the FVP group (30).The Chinese Health Ministry, after reviewing the studies, concluded that FVP was efficacious against COVID-19. In Japan, a clinical registry containing 1918 hospitalized patients receiving FVP on a compassionate use basis was released on June 2, 2020 (31). There was no control group nor data on viral clearance. Patients were treated on average 3 days post admission to the hospital. The 30 day overall mortality was 11.6%. For patients requiring supplemental oxygen, the 30 day mortality was 12.7%. A recent press conference announced that an 89 patient controlled study in Japan was inconclusive due to failure to reach statistical significance in this small cohort. In Russia, a state sponsored agency confirmed the response to FVP in an as yet unpublished study apparently comprising 700 patients and approved the drug for clinical treatment beginning in multiple hospitals on June 12, 2020. In India, Glenmark™ recently announced unpublished data on 150 patients confirming the favorable results of the Chinese studies, and the drug has been given emergency authorization for use.

Published studies on hydroxychloroquine (HCQ) have been controversial. In a small French study in Marseille, COVID-19 patients were included in a single arm protocol to receive 600mg of HCQ daily, with daily viral load testing (31). Depending on the clinical presentation, azithromycin (AZM) was added to the treatment. Untreated patients from another center and patients who refused the protocol were included as negative controls. The authors state that there was a significant reduction of viral carriage at day 6 post inclusion compared to controls. The same group subsequently reported their experience with 3737 patients screened positive for SARS-Cov-2 immediately treated with HCQ and AZM, after excluding patients at risk of QT prolongation(32,33). Asymptomatic contacts with positive viral tests were included, so most of their subjects were outpatients seen in their day hospital in addition to those who did require hospitalization. Their control population was not randomized, raising the issue of treatment bias. They showed clearance of viral shedding in 89.4% of the patients by ten days. The overall mortality in their population was 0.9%, none in patients under 60 years old, and no sudden cardiac deaths.

There have been many retrospective large observational trials which suggest that hospitalized patients on HCQ have worse outcomes with possible cardiac dysrrythmias (See TABLE 6) (38-42). The difficulty in analyzing retrospective observational data is in the possibility of selection bias choosing patients who were sicker for treatment. Propensity scoring can help adjust for bias, and comparability of groups after adjustment has been claimed. In a randomized, controlled, Brazilian study, neither HCQ nor HCQ +AZM showed any clinical benefit in mild to moderate COVID-19 hospitalized patients (43). In the randomized RECOVERY trial, in 1542 patients in the United Kingdom, there was no significant

difference in the primary endpoint of 28-day mortality (26.8% hydroxychloroquine vs. 25% usual care; hazard ratio 1.09 [95% confidence interval 0.96-1.23]; *p*=0.18) (44).

Different results were reported in a large retrospective observational study at the Henry Ford Hospital System in Detroit (45). In this study, patients were selected for treatment based on an unpublished protocol, choosing sicker patients for HCQ treatment, and HCQ+AZM for those with most severe disease, if there were no cardiac risk factors. Overall in-hospital mortality was 18.1% (95% CI:16.6%-19.7%); by treatment: HCQ+AZM, 157/783 (20.1% [95% CI: 17.3%-23.0%]), HCQ alone, 162/1202 (13.5% [95% CI: 11.6%-15.5%]), AZM alone, 33/147 (22.4% [95% CI: 16.0%-30.1%]), and neither drug, 108/409 (26.4% [95% CI: 22.2%-31.0%]). One major difference was that the HCQ patients were more likely to be hypoxic on admission and much more likely to have received glucocorticoid treatment. However, 190 patients receiving HCQ were matched to 190 patients not receiving HCQ by propensity scoring, and, in this comparison to eliminate differences, HCQ treatment reduced mortality by 51% (*p*=0.009).

In a retrospective comparison study at NYU Langone Health for all patients admitted between March 2 and April 5, 2020, there was a move to add zinc 100 mg daily to their standard HCQ plus AZM regimen(46). Zinc supplementation has shown benefit in viral diseases both in inhibiting viral replication, improvement of systemic immunity and reduction of duration of common cold symptoms (47,48). There were 411 patients treated with HCQ+AZM+ zinc. There were only minor differences in the clinical characteristics of these patients compared to 521 patients on HCQ + AZM who did not receive zinc. After adjustment for the time period when zinc first came to frequent use, there was a

significantly lower mortality (13.1%) among the zinc treated patients compared to those who did not receive zinc (22.8%).

The prevailing current opinion on HCQ treatment of COVID-19 is based almost entirely on in-hospital data, with limited study in outpatients. In one large internet-based prevention study, with HCQ given for 5 days to healthy individuals with a significant exposure to SARS-Cov-2, the incidence of new illness compatible with COVID-19 did not differ significantly between participants receiving HCQ (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%]); absolute difference −2.4 percentage points (95% confidence interval, −7.0 to 2.2; p=0.35) (49). The same group also treated 423 patients with mild symptoms imputed to COVID-19 (505). At 14 days, 24% (49 of 201) of participants receiving HCQ had ongoing symptoms compared with 30% (59 of 194) receiving placebo (p = 0.21).

A study in Spain of 293 patients with PCR-confirmed mild COVID-19, found no difference in viral load following 6 days HCQ treatment nor risk of hospitalization compared to untreated patients (51). The same group treated 1,116 healthy contacts of 672 Covid-19 index cases with HCQ while 1,198 were randomly allocated to usual care (52). There was no significant difference in the primary outcome of PCR-confirmed, symptomatic Covid-19 disease (6.2% usual care vs. 5.7% HCQ; risk ratio 0.89 [95% confidence interval 0.54-1.46]), nor evidence of prevention of SARS-CoV-2 transmission (17.8% usual care vs. 18.7% HCQ).

A large population study in Portugal surveyed all patients on chronic HCQ treatment and cross-verified against a mandatory database of patients registered with COVID-19 (53). The incidence of SARS-

CoV-2 infection in patients receiving HCQ was 5.96%, compared to 7.45% in those not so treated. The adjusted odds ratio of a positive PCR test for HCQ chronic treatment was 0.51 (0.37-0.70).

Published results with Lopanovir/ritonavir (LPV/r) in hospitalized patients have been disappointing. In a randomized trial with 99 patients on LPV/r and 100 receiving standard care, there was no difference in time to clinical improvement, mortality or viral clearance (55). A very recent press release, not yet published, from the RECOVERY trial showed no significant difference in the primary endpoint of 28-day mortality (22.1% LPV/r vs. 21.3% usual care; relative risk 1.04 [95% confidence interval 0.91-1.18];(*p*=0.58) in 1,596 hospitalized patients.

A possibly more favorable result was obtained in Hong Kong in a study of 86 patients assigned to triple combination therapy with LPV/r plus ribavirin plus interferon beta-1 (56). Compared to a control group of 41 patients receiving LPV/r alone, the combination group had a significantly shorter median time from start of study treatment to negative SARS-Cov-2 nasopharyngeal swab (7 days [IQR 5–11]) than the control group (12 days [8–15]; hazard ratio 4.37 [95% CI 1.86–10.24], *p*=0·0010). The time to complete alleviation of symptoms was 4 days [IQR 3–8] in the combination group vs 8 days [7–9] in the control group; HR 3.92 [95% CI 1.66–9.23. The timing of interferon administration was staggered based on time of symptom onset, so there were 34 patients in the combination group who did not receive interferon at all; those patients did not show clinical or virologic superiority to the LPV/r control group. This study was interpreted not as supporting LPV/r therapy, but rather focusing on interferon beta-1 as the primary treatment modality.

In Cuba, a combination of interferon beta and interferon gamma on background therapy of LPV/r and chloroquine, was successful in achieving viral clearance in 4 days in 78.6% of the patients compared to 40.6% of those receiving interferon beta alone (58). A study of 81 hospitalized patients in Iran showed 28-day overall mortality significantly lower in an interferon treated group than the control group (19% vs. 43.6% respectively, p= 0.015) (60). Early administration significantly reduced mortality (OR=13.5; 95% CI: 1.5-118). Interferon nasal drops were administered to 2944 medical staff people in Huabei province, with not a single case of COVID-19, but there was no randomized control group (61). Recently, a press release announced that a small British study of nebulized interferon beta-1 had succeeded in reducing duration of hospitalization and mortality.

There have been many studies of immunomodulatory therapy to mitigate the hyperinflammatory phase of COVID-19 which suggested reduction of mortality and need for intubation in hospitalized severe and critically ill patients (42, 63-73). Similar levels of improvement have now been reported for the IL-1 inhibitor anakinra (74,75). In a consecutively enrolled cohort of ICU patients in France, the requirement for invasive mechanical ventilation and death was significantly reduced in 52 patients who received anakinra, compared with 44 historical controls who received usual care (hazard ratio 0·22 [95% CI 0·11–0·41], p<0·0001) (75). However, a very recent press release by Roche Pharmaceuticals stated that there was no benefit of tocilizumab in the double blind COVACTA trial in clinical status, mortality(19.7% tocilizumab vs placebo = 19.4%), nor in ventilator free days.

Pre-COVID-19, glucocorticoid treatment had been a recognized treatment with mortality benefit for ICU patients in respiratory distress (76). In the RECOVERY trial, the dexamethasone arm studied 2104

patients randomly, allocated to receive this agent for ten days compared to 4321 patients concurrently allocated to usual care (78). Overall, 454 (21.6%) patients allocated dexamethasone and 1065 (24.6%) patients allocated usual care died within 28 days (age adjusted rate ratio [RR] 0.83; 95% confidence interval [CI] 0.74 to 0.92; $p<0.001$). Dexamethasone reduced deaths by one-third in the subgroup of patients receiving invasive mechanical ventilation (29.0% vs. 40.7%, RR 0.65 [95% CI 0.51 to 0.82]; $p<0.001$) and by one-fifth in patients receiving oxygen without invasive mechanical ventilation (21.5% vs. 25.0%, RR 0.80 [95% CI 0.70 to 0.92]; $p=0.002$), but did not reduce mortality in patients not receiving respiratory support at randomization (17.0% vs.13.2%, RR 1.22 [95% CI 0.93 to 1.61]; $p=0.14$). Methylprednisolone has shown similar results in COVID-19 patients with acute respiratory failure (79,80), although a short 5 day course did not alter the very high mortality in a Brazilian study (81). There is no information as yet as to whether tocilizumab or anakinra taken on a background of high dose glucocorticoid could provide any added benefit.

Colchicine, an anti-inflammatory agent, suggested benefit in the GRECCO, placebo-controlled, randomized clinical trial of 105 patients (82). The primary clinical end point of deterioration to mechanical ventilation or death was 14% in the control group (7 of 50 patients) and 1.8% in the colchicine group (1 of 55 patients) (odds ratio, 0.11; 95%CI, 0.01-0.96; p = 0.02).

There is also favorable data on convalescent plasma with a modest reduction in mortality (83,84). However, antibody levels vary in patients who have recovered from COVID-19 complicating the selection of donors (85). Two retrospective studies have suggested possible benefit with agents not

ordinarily considered antiviral. Patients on famotidine in an observational study in New York City had lower mortality,as did ivermectin treated patients reviewed in Florida (86, 87).

Several vaccines have reported successful induction of antibody in early phase trials. Four vaccines have published data suggesting strong neutralizing antibody and cellular immunity response (88-91). An inactivated Chinese vaccine has recently reported strong neutralizing antibody effects (92).

DISCUSSION

SARS-Cov-2 overwhelmed medical preparedness for the pandemic. The United States, Brazil, and Europe have been particularly hit hard. On the day of August 15, as this manuscript is being written, there were 52,799 new cases with 1,169 deaths in the USA (1). Current projections are for a continuation of new cases and deaths at least through October 2020 (93). Clinical trials to date have focused on hospitalized patients to try to prevent death. In the USA, remdesivir is now available on an emergency use basis, but only for hospitalized severely ill patients. The WHO and NIH have discontinued their studies of LPV/R and HCQ.. At this point, it is unclear if the interleukin inhibitors offer benefit beyond standard glucocorticoid treatment.

It is hoped that the availability of remdesivir and improved treatment of COVID-19 respiratory failure will lower the present rate of in-hospital mortality which still approaches 20 percent. However, it is essential to prevent and to treat the initial viral infection so that hospitalization can be avoided. We face a dilemma in having no current prevention nor treatment for outpatients with mild to moderate disease, constituting 80% of the infected population and the primary mode of spread of SARS-Cov-2.

The lessons learned in very sick hospitalized patients may not hold true in the earlier viremic phase of the disease.

The Chinese have shown that strict epidemiologic control is possible, but that approach has not been fully successful in Western countries, where two months of social distancing and quarantine devastated the economies. There is also a contrast in the medical response comparing China to the Western countries. In China, empirical treatments have been offered and officially endorsed by the China National Health Commission without proof of efficacy (17). In China, it is not the practice to run placebo-controlled trials with investigational agents without alternative choices for the patient. Consequently, their "standard of care" often includes many potentially effective agents, possibly confounding results. Unlike China, the United States and Europe emphasize randomized, placebo-controlled clinical trials to decide which agents should be widely used for treatment. Those trials are ongoing, but we found that only 40 of 164 trials are proposed to complete enrollment in the second quarter of 2020. It typically may take two months or more to follow patients to completion, verify and analyze data, and then finally publish, thus impairing the goal to find treatments to be used now and during the next six months for the ongoing pandemic.

Vaccines have been the principal hope held out by public health authorities. Progress on vaccine development has been extremely rapid, but the speed of development does not reduce the challenges of developing a vaccine to be administered to hundreds of millions of people (94). Certainly the 30 years of as yet unsuccessful efforts to produce an AIDS vaccine illustrate the worst case difficulties (95). Although neutralizing antibodies and memory T cells can be produced by the vaccine candidate, the

demonstration of true protection requires observation and long-term follow-up of an exposed vaccinated population. No matter how rapidly a vaccine advances to Phase III testing, the duration of follow-up cannot be shortened, and for SARS-Cov-2 possibly prolonged due to several factors. First, there is a risk of immune enhancement of infection which occurs when induced antibodies increase entry and internalization of virus into myeloid cells (96). This major complication struck the newly developed dengue vaccine in 2017 (97). Second, the sinister autoimmune pathogenicity of SARS-Cov-2, evidenced by multisystem inflammatory disorder in children, raises the risk of delayed long-term harm if the virus is not fully and immediately eradicated by the initial immune response to the vaccine. Finally, the duration of protection is an open question. Studies of recurrent coronavirus infections suggest that infection may confer immunity for less than a year (98). For these reasons of needed long term safety observation, the deployment of an effective vaccine could be delayed. An alternative approach now is to increase the non-specific immune reaction to the initial infection. Vaccination with oral polio vaccine to provide heterologous immunity has been suggested by Drs. Chumakov and Gallo, but that vaccine is no longer as freely available as their alternative suggestion of BCG vaccine (23, 99). There are very large prevention trials now being conducted in the Netherlands and Australia using BCG vaccination to increase innate immunity to SARS-Cov-2 in health care workers, but those are not due to complete until the fourth quarter of 2020.

Shortages of testing supplies in the United States have thus far limited the ability to positively diagnose the disease, resulting in the recommendation of home quarantine for the majority of patients with suspicious symptoms. Those shortages are being rapidly remedied. Now, there is a need for therapeutic interventions which can be used to treat outpatients with positive COVID-19 tests at the

time of initial symptoms, not waiting for deterioration requiring hospital care. The Marseille group demonstrated that it was possible to treat all outpatients with a positive test early in the viremic phase of COVID-19 (34). They provided clinical and virologic data, but without a well-defined control group to justify their treatment with HCQ plus AZM. The NYU group treated all hospitalized patients with HCQ and AZM, and showed an impressive effect of addition of zinc sulfate, but they had no control group for HCQ plus AZM. Remdesivir is administered intravenously, so not a practical daily outpatient treatment. Gilead© is attempting to develop an inhaled remdesivir formulation, but those efforts are only now beginning. Favipiravir, a tablet, could be used in early stages of infection and has now been released for that purpose in Russia and in India, but not in the United States. It has known embryogenic risks, so its use requires restrictions on women of childbearing potential, as is the case with tretinoin for acne and thalidomide for multiple myeloma. Trials with camostat, the serine protease inhibitor, capable of blocking cell entry of SARS-Cov-2, are not due to end till the third or fourth quarter of the year. Similarly, a prevention trial with colchicine is not scheduled to end until the fourth quarter of 2020. The Solidarity Trial interferon arm is not scheduled to complete enrollment until 2021. So, none of the possible therapeutic interventions have been proven successful in randomized, placebo-controlled studies. There are strong arguments to avoid emergency use of agents until trials are completed and analyzed, but the agents suggested are not new (100). Most of them are drugs like interferon, marketed for other conditions and with well-known safety profiles.

There is a precedent to resolve the conflict between immediate clinical need and the requirements for rigorous controlled trials to prove efficacy. We should remember that the greatest success in fighting a pandemic occurred over the past two decades in the battle against the HIV virus which causes AIDS.

AIDS was first recognized in 1981 in the gay community (101). The disease was considered a death sentence. There was widespread fear because there was no treatment, and projections of infection escalated into the millions. The first AIDS remedy was azidothymidine (AZT), synthesized in 1964 in the hope that it would combat cancer. Twenty years later Dr. Samuel Broder, head of the National Cancer Institute, showed that the drug had activity against the HIV virus in vitro (102). Burroughs Wellcome launched a rapidly conceived trial with just 300 patients. They stopped the trial in 16 weeks claiming that more patients survived on AZT. The FDA came under enormous pressure from AIDS activists to make the drug available, and it was approved on March 19, 1987, with only that one trial. It had taken 20 months for the FDA to give approval to release the drug. To this day, the design and results of the trial remain controversial.

The gay community continued to battle for early release of other medications to combat the AIDS pandemic. On October 11, 1988, a massive protest occurred at the FDA. It was back then Dr. Anthony Fauci who publicly advanced the idea of a parallel track to make drugs widely available even while studies are progressing: "*Clearly, the standard approach to the design of clinical trials—that is, rigid eligibility criteria as well as the strict regulatory aspects that attend clinical trial investigations and drug approval—was not well-suited to a novel, largely fatal disease such as this with no effective treatments, and we had many intense discussions about how to make that approach more flexible and ethically sound. One example, which I and others worked closely with the AIDS activists to develop, was called a parallel track for clinical trials. The parallel track concept, which the United States Food and Drug Administration ultimately came to support, meant that there would be the standard type of highly controlled admission criteria and data collection for the clinical trial of a particular drug. In*

parallel, however, the drug also could be made available to those who did not meet the trial's strict admission criteria but were still in dire need of any potentially effective intervention, however unproven, for this deadly disease" (103).

The parallel track advocated by Dr. Fauci was adopted. Today, there are 41 drugs or combinations approved by the FDA to treat and to prevent HIV infection. There is still no vaccine. There are now an estimated 1.1 million patients with HIV in the United States, most enjoying near normal life expectancy thanks to the antiviral agents. The CDC has contributed greatly to limit the spread of HIV by advocating safe sex practices, but social distancing is not the norm for HIV. Rather "treatment as prevention" for people with HIV using highly active antiretroviral regimens to prevent transmission and pre-exposure prophylaxis endorsed by the CDC with a daily antiviral combination pill is currently adopted in wide segments of the at risk population (104).

In this pandemic crisis, we appeal to public health authorities to cross institutional, commercial and international boundaries to collate and combine all randomized controlled data submitted for all agents in Europe, China, Russia, Japan and other countries, and by competing companies, whether officially published, posted on line, or unpublished to finalize confirmatory results. The Solidarity Trial is a model of what could and should be done to unify a worldwide effort to pursue studies in outpatients. At the same time, agents with favorable preliminary results and no safety issues should be made available through a parallel track. In Russia and India, the parallel track has been fully implemented, with FVP now offered as treatment throughout both countries, even as further confirmatory controlled trials proceed. Interferon beta is one of the remaining randomized controlled Solidarity Trial options and is

widely available in most countries. If vaccines can be brought forward now, it is reasonable to authorize their use at present in very large parallel track studies in at risk populations, such as healthcare workers and the elderly. However, it is likely that combination antiviral medications in addition to vaccination will likely be needed to stop SARS-Cov2. It is necessary for public health authorities to make hard decisions now despite limited current data and offer treatments without further delay.

REFERENCES

1) 420WHO Coronavirus Disease (COVID-19) Dashboard

Data last updated: 2020/8/15, 4:35pm

2) Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239-1242

3) Rajgor DD, Har Lee M, Archuleta, S, et al. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis. 2020 Jul; 20(7): 776–777.

4) Russell TW, Hellewell J, Jarvis CI, et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. Euro Surveill. 2020 Mar 26; 25(12): 2000256.

5) Wang D, Yin Y, Hu C, et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. Critical Care. 2020; 24: 188

6) Huang C, Wang Y, Li X et al Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 2020; 395: 497–506

7) Chen T, Wu D, Chen H, et al.Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.

8) Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–62

(9) Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020 Apr 17.

(10) Ricardo J Jose, Ari Manuel. COVID-19 cytokine storm: the interplay between inflammation and coagulation storm: Lancet Respir Med 2020 Published Online April 27, 2020

11) Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020; 383:334-346

12) Cousins S. New Zealand eliminates COVID-19. Lancet Published:May 09, 2020

13) (https://chp-dashboard.geodata.gov.hk/covid-19/en.html;

14) https://www.nature.com/articles/d41586-020-01248-1

15) Kissler SM, Tedijanto C, Goldstein E et al. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period Science 2020;10.1126/science.abb5793 (2020

16) Park M, Ryan S, Thwaites RS, et al. COVID-19: Lessons from SARS and MERS First published:27 February 2020 Eur J Immun https://doi.org/10.1002/eji.202070035

17) China National Health Commission. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition 2020-03-16 12:00:32

18) Liu J, Cao R, Xu M,et al. Cell Discovery. 2020; 6:16 Cell Discovery https://doi.org/10.1038/s41421-020-0156-0www.nature.com/celldisc

19) Thorlund KT, Dron L, Park J et al. A real-time dashboard of clinical trials for COVID-19. Lancet Digital Health published on line 24 Apr 20 https://doi.org/10.1016/ S2589-7500(20)30086-8

20) Ngo BT, Rendell M. A systematic analysis of the time course to develop treatments for COVID-19medRxiv 2020.05.27.20115238; doi: https://doi.org/10.1101/2020.05.27.20115238

21) "'Solidarity' clinical trial for COVID-19 treatment". www.who.int. World Health Organization. Retrieved 22 April 2020

22) Haviernik J, Štefánik M, Fojtíková M et al. Arbidol (Umifenovir): A broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses. 2018 Apr; 10(4): 184.

23) Uno Y. Camostat mesilate therapy for COVID-19. Intern Emerg Med. 2020 Apr 29

24) Chumakov K, Benn CS, Aaby P, et al. Can existing live vaccines prevent COVID-19? Science 2020; 368: 1187-1188

25) Wang Y, Zhang D, Guanhua Du G, et al. Remdesivir in adults with severe COVID-19: a randomised,double-blind, placebo-controlled, multicentre trial. Lancet Published Online April 29, 2020 https://doi.org/10.1016/ S0140-6736(20)31022-9

26) Grein J, Ohmagari N, Shin D. Compassionate use of remdesivir for patients with severe Covid-19N Engl J Med April 10, 2020

27) Beigel JH, Tomashek KM, Dodd LE. Remdesivir for the Treatment of Covid-19 — Preliminary Report. May 22, 2020. New Engl J Med. DOI: 10.1056/NEJMoa2007764

28) Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. New Engl J Med May 27, 2020 DOI: 10.1056/NEJMoa2015301

29) Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study Engineering (In Press)

30) Chen C, Huang J, Zhenshun Cheng Z, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037432.this version posted March 20, 2020.

31) Preliminary Report of the Favipiravir Observational Study in Japan Favipiravir Observational Study Group. http://www.kansensho.or.jp/uploads/files/topics/ 2019ncov/ covid19_casereport_ en_200529.pdf Accessed 19 June 2020

32) Gautret P ,Lagier J-C , Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents (In Press)

33) Million M, Lagierab J-C, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Medicine and Infectious Disease (In Press) Available online 5 May 2020

34) Lagier JC, Million M, Gautret P, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Medicine and Infectious Disease (In Press). Available on line 25 June 2020

35) Chen Z, Hu J,Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv preprint doi:https://doi.org/10.1101/2020.03.22.20040758.this version posted March 30, 2020.

36) Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) J Zhejiang Univ (Med Sci) 2020, Vol. 49 Issue (1): 0-0 DOI: 10.3785/j.issn.1008-9292.2020.03.03

37) Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial. BMJ 2020;369:m1849

38) Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. medRxiv 2020; published online April 23. DOI:10.1101/2020.04.16.20065920 (preprint).

39) Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. New England Journal of Medicine Downloaded from nejm.org on May 13, 2020.

40) Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. doi:10.1001/jama.2020.8630 Published online May 11, 2020.

41) Mahévas M, Tran VT, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020;369:m1844

42) Ip A, Berry DA, Hansen E, et al, Hydroxychloroquine and tocilizumab therapy in COVID-19 patients - An observational study. MedRxiv https://doi.org/10.1101/2020.05.21.20109207

43) Cavalcanti AB,. Zampieri FG, Rosa RG, et al .Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New Eng J Med published on line July 23, 2020 DOI: 10.1056/NEJMoa2019014

44) RECOVERY Collaborative Group. Effect of Hydroxychloroquine in hospitalized patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. medRxiv preprint doi: https://doi.org/10.1101/2020.07.15.20151852

45) Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Inf Dis. https://doi.org/10.1016/ j.ijid.2020.06.099

46) Carlucci P, Tania Ahuja T, Petrilli CM, et al. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients medRxiv doi: https://doi.org/10.1101/2020.05.02.20080036

47) Read SA, Obeid S,Ahlenstiel C, et al. The role of zinc in antiviral immunity. Adv Nutr. 2019 Jul; 10(4): 696–710.Published online 2019 Apr 22

48) Singh M, Das RR. Zinc for the common cold. Cochrane Database Syst Rev. 2015 Apr; 2015(4): CD001364. Published online 2015 Apr 30.

49) Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med June 3, 2020 DOI: 10.1056/NEJMoa2016638

50) Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19.A randomized trial. Ann Int Med published on line 16 Jul 2020

51) Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial. Clinical Infectious Diseases, ciaa1009, https://doi.org/10.1093/cid/ciaa1009 Published: 16 July 2020

52) Mitjà O, Ubals M, Corbacho-Monné M, et al. A cluster-randomized trial of hydroxychloroquine as prevention of Covid-19 transmission and disease. medRxiv 2020.07.20.20157651; doi: https://doi.org/10.1101/2020.07.20.20157651

53) Ferreira A, Oliveira-e-Silva A ,Bettencourt P. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. medRxiv preprint doi: https://doi.org/10.1101/2020.06.26.20056507. posted June 29, 2020

54) Li Y, Xie Z, Lin W, et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI. medRxiv preprint doi: https://doi.org/10.1101/2020.03.19.20038984.this version posted

55) Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282.

56) Hung IFN , Lung KC, Tso EYK,Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial Lancet, published on line 8 may 2020https://doi.org/10.1016/

57) Estebanez M, Ramirez-Olivencia G, Mata T, et al. Clinical evaluation of IFN beta1b in COVID-19 pneumonia: a retrospective study. MedRxiv doi: https://doi.org /10.1101/ 2020.05.15.20084293

58) Pereda R, González D, Rivero HB, et al. Therapeutic effectiveness of interferon-alpha 2b against COVID-19: the Cuban experience. medRxiv preprint doi: https://doi.org/10.1101/2020.05.29.20109199.

59) PE Idelsis, Perez-Escribano J, Duncan-Robert Y, et al Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA medRxiv https://doi.org/10.1101/2020.07.29.20164251

60) Davoudi-Monfared E, Rahman H, Khalili H. Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial. MedRxiv doi: https://doi.org /10.1101/2020.05.28.20116467

61) Meng Z, Wang T, Chen L, et al. An experimental trial of recombinant human interferon alpha nasal drops to prevent COVID-19 in medical staff in an epidemic area. medRxiv .https://doi.org/10.1101/2020.04.11.20061473

62) Bian H, Zhao-Hui Zheng ZH, Ding Wei D. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. medRxiv doi:https://doi.org/10.1101/2020.03.21.20040691

63) Xua X, Hanb M, Lia T, et al. Effective treatment of severe COVID-19 patients with tocilizumab 10970–10975 | PNAS | May 19, 2020 | vol. 117 | no. 20
www.pnas.org/cgi/doi/10.1073/pnas.2005615117

64) Somers EC, Eschenauer GA, Troost JP. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. MedRxiv doi: https://doi.org/10.1101/2020.05.29.20117358

65) Rossi B, Nguyen LS, Zimmermann, et al Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study medRxiv doi: https://doi.org/ 10.1101/2020.06.06.20122341

66) Martinez-Sanz J, Muriel A, l Ron R, et al. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: A Multicenter Cohort Study. MedRxiv doi:
https://doi.org/10.1101/2020.06.08.20125245

67) Petrak R, Skorodin N, Van Hise N, et al. Tocilizumab as a therapeutic agent for critically ill patients infected with SARS-CoV-2. MedRxiv doi: https://doi.org/10.1101/ 2020.06.05.20122622

68) Perrone P, Piccirillo MC, Ascierto PA, et al. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial. MedRXiv doi: https://doi.org/10.1101/2020.06.01.20119149

69) Garcia EM, Caballero VR, Albiach L,et al. Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection medRxiv doi: https://doi.org/ 10.1101/2020.06.05.20113738

70) Wadud N, Ahmed N, Shergil M, et al. Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration. MedRxiv doi: https://doi.org/10.1101/2020.05.13.20100081

71) Sanchez-Montalva A, Selares-Nadal J, Espinosa-Pereiro J, et al. Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study.doi: https://doi.org/10.1101/2020.05.07.20094599

72) Ramaswamy M, Mannam P, Comer R, et al. Off-label real world experience using tocilizumab for patients hospitalized with COVID-19 disease in a regional community health system: A case-control study medRxiv. doi: https://doi.org/10.1101/2020.05.14.20099234

73) Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020 Published Online June 24, 2020 https://doi.org/10.1016/ S2665-9913(20)30173-9

74) Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2020; 2: e325–31

75) Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol 2020; published online May 29.https://doi.org/10.1016/S2665-9913(20)30164-8.

76) Villar J, Ferrando C, Martínez D et al. Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial. Lancet Respir Med. 2020;8:267-276.67

77) Chroboczek T, Lacoste L, Wackenheim C, et al. Beneficial effect of corticosteroids in severe COVID-19 pneumonia: a propensity score matching analysis. MedRxiv: doi: https://doi.org/ 10.1101/2020.05.08.20094755

78) RECOVERY Collaborative Group. Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report. July 17, 2020 DOI: 10.1056/NEJMoa2021436

79) Salton F, Confalonieri P, Santus P. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. medRxiv preprint doi: https://doi.org/10.1101/2020.06.17.20134031.this version posted June 25, 2020

80) Villar J, Confalonieri, M,; Pastore, SM, et al. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by Coronavirus Disease 2019. Crit Care Explor April 2020;2 :e0111

81) Jeronimo CMP, Farias MEL, BSc, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): A randomised, double-blind, phase iib, placebo-controlled trial Clinical Infectious Diseases, ciaa1177, https://doi.org/10.1093/cid/ciaa1177

82) Deftereos SG, Giannopoulos G, Dimitrios A, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with Coronavirus Disease 2019. The GRECCO-19 randomized clinical trial. JAMA Network Open. 2020;3:e2013136.

83) Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. Published online June 3, 2020. doi:10.1001/jama.2020.10044

84) Perotti C, Baldanti F, Bruno R, et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial. medRxiv doi: https://doi.org/10.1101/2020.05.26.20113373

85) Luchsinger LL, Ransegnola B, Jin D, et al. Serological analysis of New York City COVID19 convalescent plasma donors. medRxiv. doi: https://doi.org/10.1101/2020.05.14.20099234

86) Freedberg DE, Conigliaro J, Sobieszczyk ME, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study medRxiv preprint doi: https://doi.org/10.1101/2020.05.01.20086694

87) Rajter JC, Sherman M, Fatteh N, et al. ICON (Ivermectin in COvid Nineteen) study: Use of ivermectin is associated with lower mortality in hospitalized patients with COVID19. medRxiv doi: https://doi.org/10.1101/2020.06.06.20124461

88) Folegatti PM, J Ewer KJ, Parvinder K Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised

controlled trial. Lancet Published Online July 20, 2020 https://doi.org/10.1016/S0140-6736(20)31604-4

89) Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 — preliminary report July 14, 2020, at NEJM.org. DOI: 10.1056/NEJMoa2022483

90) Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo controlled, phase 2 trial. Lancet. Published Online July 20, 2020 https://doi.org/10.1016/S0140-6736(20)31605-6.

91) Keech C,, Glenn GM, Albert Get al..First-in-human trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine medRxiv .https://doi.org/10.1101/2020.08.05.20168435doi: posted August 6, 2020

92) Xia S, Duan K, Yuntao Zhang Y,; et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes. Interim analysis of 2 randomized clinical trials. JAMA. Published online August 13, 2020. doi:10.1001/jama.2020.15543

93) Liu M, Thomadsen R, Yao S. Forecasting the spread of COVID-19 under different

reopening strategies. medRxiv preprint doi: https://doi.org/10.1101/2020.05.26.20113993

)

94) Diamond MS, Pierson TC. The challenges of vaccine development against a new virus during a pandemic. Cell Host Microbe. 2020;27(5):699-703.

95) Burton DR. Advancing an HIV vaccine; Advancing vaccinology. Nat Rev Immunol 2019 ;19(2):77-78

96) Wan Y, Shang J, Sun S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J. Virol. 2020;94:e02015-19.

97) Fatima K, Syed NI. Dengvaxia controversy: impact on vaccine hesitancy. J Glob Health. 2018; 8(2): 020312.

98) Edridge AWD, Kaczorowska J, Hoste ACR et al. Coronavirus protective immunity is short-lasting medRxiv preprint doi: https://doi.org/10.1101/2020.05.11.20086439.this version posted June 16, 2020.

99) Moorlag SJCFM, Arts RJW, van Crevel R, et al. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. (2019)

100) Goodman JL, Borio L. Finding effective treatments for COVID-19. Scientific integrity and public confidence in a time of crisis. JAMA. 2020;323(19):1899-1900. doi:10.1001/jama.2020.64

101) Sepkowitz KA. AIDS-The first 20 years. N Engl J Med 2001; 344:1764-1772

102) Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010; 85: 1-18

103) Fauci AS. Preface: Evolving ethical issues over the course of the AIDS pandemic. Public Health Rev 34, 2 (2012)

104) Harris NS, Johnson AS, Huang YA, et al. Vital Signs: Status of human immunodeficiency virus testing, viral suppression, and HIV pre-exposure prophylaxis - United States, 2013-2018. MMWR Morb Mortal Wkly Rep. 2019 68:1117-1123

NUMBER OF REGISTERED TRIALS	
>100	China (323) United States (103)
>30	Spain (36) France (35)
>20	Iran (29) Italy (21)
>10	Germany (19) Canada(18) Netherlands(14) Brazil(13) Denmark(13) Japan (12) United Kingdom(12)
>5	Israel (9), Pakistan (9),Egypt (8) Mexico (8) South Korea (8)Belgium (6), Greece (6)
5	Colombia , Norway,Switzerland
4	Australia , Austria, India , Russia , Singapore , Thailand
3	Nigeria, South Africa, Sweden,Tunisia
2	Argentina, Hungary, Ireland, Poland, Qatar,Taiwan
1	Bahrain, Cuba, Czechia, Indonesia, Iraq, Jordan, Macedonia, Malaysia, Monaco, New Zealand, Peru, Puerto Rico

TABLE 1. TRIALS IN EACH COUNTRY. Number of trials registered in various countries per WHO

TABLE 2. STUDIES WITH ANTIMALARIALS, LOPANOVIR/RITONAVIR, OR INTERFERONS. The setting of each study, whether hospital or outpatient, the type of control (AC: Active control, RCT: randomized control; soc: standard of care; PLAC: placebo control, whether treatment (TREAT) or prevention (PREV), the severity of illness, number of subjects, quarter study initiated, quarter study projects completion of enrollment, and duration of symptoms for patient inclusion are listed. Studies projecting completion of enrollment by the end of the second quarter of 2020 are bolded. Outpatient studies with planned completion by the end of the second quarter of 2020 are italicized.

OUTPATIENT OR HOSPITAL	TYPE OF CONTROL	PREVENTION OR TREATMENT	SEVERITY OF ILLNESS	NO OF SUBJECTS	BEGIN DATE	PROPOSED END OF ENROLLMENT	DURATION SYMPTOMS
				HCQ OR CHLOROQUINE			
OUT	RCT,PLAC	PREV (6)	HEALTHY, EXPOSED	360,3500,440,400,350,1700	Q1(20),Q2(20)	3 Q3(20), 2 Q4(20), 1 Q2(21)	N/A
OUT	AC azithromycin, AC LPV/r	PREV (2)	HEALTHY, EXPOSED	900,1200	Q1(20),Q2(20)	1 Q3(20, 1Q4(20)	N/A
OUT	RCT PLAC	PREV,TREAT	HEALTHY EXPOSED, MILD	3000	Q1(20)	***Q2(20)***	4
OUT	AC ascorbic acid	PREV	HEALTHY EXPOSED	2000	Q2(20)	Q3(20)	4
OUT	AC ascorbic acid	TREAT	MILD,MOD	1250	Q2(20)	Q3(21)	2
OUT	AC azithromycin	TREAT	MILD,MOD	1550	Q2(20)	Q1(21)	7
OUT	RCT PLAC	TREAT, PREV	MILD, HEALTHY EXPOSED	3040	Q1(20)	***Q2(20)***	5
OUT	RCT PLAC	TREAT	MILD	210	Q1(20)	NO DATE	7
OUT	MULTIDOSE PLAC	TREAT	MILD	400	Q2(20)	Q2(21)	ANY DUR
OUT	ac (azithromycin+hcq,hcq)	TREAT	MILD	160	Q2(20)	Q2(21)	ANY DUR
OUT	RCT PLAC	TREAT	MILD	1660	Q1(20)	Q3 (20)	4
OUT	AC (lpv/r)	TREAT	MILD	150	Q1(20)	***Q2(20)***	ANY DUR
MIXED	AC azithromycin	TREAT	MOD,SEV	600	Q2(20)	Q2(21)	7
MIXED	RCT PLAC	TREAT	MIXED	210	Q2(20)	Q3 (20)	ANY DUR
HOSP	AC azithromycin	TREAT (4)	MOD, SEV	630;500;226;300	Q2(20)	Q3,Q4(20)	ANY DUR
HOSP	AC, azithromycin	TREAT	SEV,CRIT	440	Q1(20)	Q3 (20)	ANY DUR
HOSP	RCT PLAC	TREAT	MILD,MOD	300	Q2(20)	Q4(20)	3
HOSP	RCT PLAC	TREAT	MIXED	250	Q1(20)	**Q2(20)**	2
HOSP	AC (resdemevir)	TREAT	MOD, SEV	700	Q1(20)	NO DATE	ANY DUR
HOSP	AC (lpv/r,losartan,PLAC)	TREAT	MOD, SEV	4000	Q1(20)	NO DATE	3
HOSP	AC (lpv/r,baricitinib,sarilumab,PLAC)	TREAT	MOD, SEV	1000	Q1(20)	Q1(21)	ANY DUR

HOSP	AC (faviparavir)	TREAT	MOD, SEV	150	Q1(20)	Q1(21)	14
HOSP	RCT PLAC	TREAT	MOD, SEV	202	Q1(20)	**Q2(20)**	ANY DUR
HOSP	RCT PLAC	TREAT	MOD, SEV	350	Q2(20)	**Q2(20)**	5
HOSP	AC (faviparavir)	TREAT	SEV	150	Q1(20)	**Q2(20)**	14
HOSP	AC(chq,hcq)	TREAT	SEV	100	Q1(20)	Q2(21)	14
HOSP	RCT PLAC	TREAT	SEV	510	Q2(20)	Q3 (20)	10
HOSP	AC (azithromycin)	TREAT	SEV,CRIT	276	Q2(20)	Q3 (20)	3
HOSP	RCT PLAC	TREAT	SEV,CRIT	1000	Q2(20)	NO DATE	ANY DUR
HOSP	RCT PLAC	TREAT	CRIT	500	Q1(20)	Q4(20)	ANY DUR
HOSP	AC(high vs low dose HCQ)	TREAT	CRIT	440	Q1(20)	Q3 (20)	ANY DUR
HOSP	AC (hcq +/- famotidine)	TREAT	SEV	1200	Q2(20)	Q3 (20)	1
HOSP	RCT (PLAC)	TREAT	SEV	220	Q2(20)	Q1(21)	ANY DUR
HOSP	RCT (PLAC)	TREAT	SEV	1300	Q2(20)	Q3(20)	2
HOSP	RCT (PLAC)	TREAT	MIXED	626	Q2(20)	Q3 (20)	3
OUT	RCT(soc)	TREAT	MILD	400	Q2(20)	NO DATE	ANY DUR
				LOPANOVIR/RITANOVIR			
OUT	AC HCQ	PREV (2)	HEALTHY	1200,1220	Q2(20)	***Q2(20),***Q3(21)	N/A
OUT	AC HCQ	TREAT	MILD, MOD	150	03/20/20	***Q2(20)***	ANY DUR
Mixed	AC(Mulitple)	TREAT	MIXED	500	04/20/20	Q4(20)	ANY DUR
Mixed	AC (Ebastine)	TREAT	MIXED	100	02/20/20	Q1(20)	ANY DUR
Mixed	AC (Carrimycin)	TREAT	MIXED	520	02/20/20	Q1(21)	ANY DUR
Mixed	AC HCQ	TREAT	MIXED	112	02/20/20	Q4(20)	ANY DUR
Hosp	AC HCQ,losartan	TREAT	MOD,SEV	4000	04/20/20	Q1(21)	3
Hosp	AC HCQ IFN, STEROID	TREAT	SEV	5000	02/20/20	**Q2(20)**	ANY DUR
HOSP	RCT(soc)	TREAT	SEV	160	Q1(20)	Q1(21)	ANY DUR
HOSP	RCT (soc)	TREAT	MILD	328	Q1(20)	Q1(21)	7
				INTERFERON			
OUT	AC (thymosin)	PREV	HEALTHY	2944	Q1(20)	***Q2(20)***	N/A
OUT	AC(chimed)	TREAT	MILD	238	Q1(20)	Q1(22)	Q2(22)
MIXED	RCT (soc)	TREAT	MIXED	328	Q1(20)	**Q2(20)**	7
MIXED	AC(ebastine)	TREAT	MIXED	100	Q1(20)	Q1(20)	ANY DUR
MIXED	AC (super compunded ifn)	TREAT	MIXED	100	Q1(20)	Q3 (20)	ANY DUR
MIXED	AC(ifn+umifenovir,umifenovir)	TREAT	MIXED	100	Q1(20)	**Q2(20)**	ANY DUR
HOSP	AC(lpv/r, hcq, steroids))	TREAT	MIXED	5000	Q1(20)	Q2(21)	ANY DUR
HOSP	RCT (PLAC)	TREAT	MILD,MOD	400	Q1(20)	NO DATE	1

AGENT	HOSPITAL OR OUTPATIENT	TYPE OF CONTROL	TREAT OR PREVENT	SEVERITY	NUMBER SUBJECTS	BEGIN DATE	PROPOSED ENROLLMENT END	DISEASE DURATION
FAVIPIRAVIR	HOSP	RCT PLAC	TREAT	MIXED	210	Q2(20)	Q3 (20)	ANY DUR
	HOSP	ac (umifenovir)	TREAT	MIXED	240	Q1(20)	**Q2(20)**	12
	HOSP	AC(fvp, fvp combined with tociluzimab,soc)	TREAT	MIXED	150	Q1(20)	**Q2 (20)**	ANY DUR
	HOSP	AC (fvp, fvp combined with chloroquine,soc)	TREAT	MIXED	150	Q1(20)	Q3 (20)	ANY DUR
	HOSP	AC (fvp+hcq, lpv+hcq)	TREAT	MOD,SEV	324	Q2(20)	Q3 (20)	ANY DUR
UMIFENOVIR	OUT	RCT(PLAC)	TREAT	MILD	380	Q1(20)	Q4(20)	ANY DUR
	MIXED	AC(lpv/r)	TREAT	MIXED	125	COMPLETED		ANY DUR
	MIXED	AC (azithromycin)	TREAT	MIXED	100	Q1(20)	**Q2(20)**	ANY DUR
	HOSP	AC(lpv/r, oseltamavir)	TREAT	MOD, SEV	400	Q1(20)	**Q2(20)**	ANY DUR
	HOSP	AC (umifenovir+hcq , hcq+lpv)	TREAT	MIXED	200	Q2(20)	Q3 (20)	ANY DUR
	HOSP	AC (umifenovir+hcq , hcq+lpv)	TREAT	MIXED	100	Q2(20)	Q3 (20)	ANY DUR
CAMOSTAT	MIXED	RCT (PLAC)	TREAT	MIXED	580	Q1(20)	Q4(20)	2
	HOSP	AC hcq+azithromycin, camostat+hcq,soc)	TREAT	MILD, MOD	250	Q2(20)	Q3 (20)	ANY DUR
EMITRICITABINE/TENOFOVIR	OUT	AC (hcq,PLAC)	PREV	HEALTHY	4000	Q2(20)	Q3 (20)	N/A
RIBAVIRIN	HOSP	AC (lpv/r+ifn b, ribavirin +lpv/r+ifn b)	TREAT	MILD, MOD	108	Q1(20)	Q1(21)	ANY DUR
REMDESIVIR	HOSP	AC(hcq+remdesivir, hcq)	TREAT	MIXED	700	Q1(20)	Q3 (20)	ANY DUR
TRIAZAVIRIN	HOSP	RCT (PLAC)	TREAT	MOD, SEV	240	Q1(20)	**Q2 (20)**	ANY DUR
IVERMECTIN	MIXED	RCT (soc)	TREAT	MIXED	100	Q2(20)	Q3 (20)	ANY DUR

TABLE 4: ANTIVIRAL AGENTS. The setting of each study, whether hospital or outpatient, the type of control (AC: Active control, RCT: randomized control; soc: standard of care; PLAC: placebo control, whether treatment (TREAT) or prevention (PREV), the severity of illness, number of subjects, quarter study initiated, quarter study projects completion of enrollment, and duration of symptoms for patient inclusion are listed. Studies projecting completion of enrollment by the end of the second quarter of 2020 are bolded. Outpatient studies with planned completion by the end of the second quarter of 2020 are italicized.

TABLE 4: IMMUNE MODULATORS. The setting of each study, whether hospital or outpatient, the type of control (AC: Active control, RCT: randomized control; soc: standard of care; PLAC: placebo control, whether treatment (TREAT) or prevention (PREV), the severity of illness, number of subjects, quarter study initiated, quarter study projects completion of enrollment, and duration of symptoms for patient inclusion are listed. Studies projecting completion of enrollment by the end of the second quarter of 2020 are bolded.

AGENT	HOSPITAL OR OUTPATIENT	TYPE OF CONTROL	TREAT OR PREVENT	SEVERITY	NUMBER SUBJECTS	BEGIN DATE	PROPOSED ENROLLMENT END	DISEASE DURATION
SARILUMAB	HOSP	RCT (PLAC)	TREAT	SEV,CRIT	300	Q1(20)	Q3 (20)	ANY DUR
	HOSP	RCT (PLAC)	TREAT	SEV,CRIT	400	Q1(20)	Q1(21)	ANY DUR
	HOSP	RCT (soc)	TREAT	SEV,CRIT	460	Q2(20)	NO DATE	ANY DUR
CD24F (blocks disinhibition of immune checkpoint)	HOSP	RCT (PLAC)	TREAT	SEV	230	Q1(20)	Q2(21)	ANY DUR
COLCHICINE	OUT	RCT (PLAC)	TREAT	MILD	6000	Q1(20)	Q3 (20)	1
	HOSP	RCT (soc)	TREAT	SEV	2500	Q2(20)	Q3 (20)	ANY DUR
IFX1 (monoclonal ab to complement)	HOSP	RCT (PLAC)	TREAT	SEV	130	Q1(20)	NO DATE	14
SELINEXOR	HOSP	RCT (PLAC)	TREAT	SEV	230	Q2(20)	Q3 (20)	ANY DUR
SILTUXIMAB	HOSP	AC (methlyprednisolone)	TREAT	SEV,CRIT	200	Q2(20)	**Q2 (20)**	ANY DUR
TOCILIZUMAB	MIXED	AC (azithromycin + hcq)	TREAT	SEV	276	Q2(20)	Q3 (20)	ANY DUR
	HOSP	AC sarilumab)	TREAT	SEV	200	Q1(20)	Q2(21)	ANY DUR
	HOSP	RCT (soc)	TREAT	SEV,CRIT	188	Q1(20)	**Q2(20)**	ANY DUR
	HOSP	RCT(PLAC)	TREAT	CRIT	330	Q1(20)	**Q2(20)**	ANY DUR
	HOSP	RCT(PLAC)	TREAT	CRIT	100	Q2(20)	Q3(20)	ANY DUR

	HOSP	AC (anakinra, siltuximab, PLAC)	TREAT	CRIT	342	Q2(20)	Q3(20)	ANY DUR
	HOSP	RCT (PLAC)	TREAT	MIXED	180	Q2(20)	Q2(22)	ANY DUR
LENZILUMAB	HOSP	RCT (PLAC)	TREAT	MOD,SEV	238	Q2(20)	Q3 (20)	ANY DUR
TJ003234 anti-GM-CSF monoclonal ab	HOSP	RCT (PLAC)	TREAT	SEV,CRIT	144	Q2(20)	Q3 (20)	ANY DUR
THYMOSIN	HOSP	AC(PD-1)	TREAT	SEV	120	Q1(20)	Q1(21)	ANY DUR
CM4620 CRAC channel inhibitor	HOSP	RCT (soc)	TREAT	SEV	144	Q2(20)	Q3 (20)	ANY DUR
LERONLIMAB	HOSP	RCT (PLAC)	TREAT	SEV,CRIT	390	Q2(20)	Q4(20)	ANY DUR
ECULIZIMAB	HOSP	RCT soc)	TREAT	SEV,CRIT	120	Q2(20)	Q3 (20)	ANY DUR
CYTOKINE PROTEIN	HOSP	RCT (soc)	TREAT	MIXED	480	Q1(20)	**Q2(20)**	8
AVDORALIMAB	HOSP	RCT (PLAC)	TREAT	SEV,CRIT	108	Q2(20)	Q3 (20)	ANY DUR

COUNTRY	NAME	PROGRESS	NUMBER SUBJECTS	TYPE OF VACCINE	DATE BEGUN	COMPLETION DATE
United Kingdom	ChAdOx1 nCov-19	PHASE I/11	510,1090	attenuated adenovirus expressing spike protein	Q1(20)	Ongoing
China	PicoVacc	PHASE I/11	744	inactivated coronavirus	Q2(20)	Q4(21)
China		PHASE I/11	100	lentiviral vector	Q1(20)	Q3(23)
United States	mRNA-1273	PHASE I/II, PHASE 3 START LATE JULY	105	Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV.	Q1(20)	Q3(21)
United States	NVX-CoV2373	PHASE I/II		Recombinant spike protein in nanoparticles	Q2(20)	Ongoing
United States, Germany	BNT162-01	PHASE I/II		mRNA vaccine	Q2(20)	Ongoing
China	Ad5-nCoV	PHASE II,VACCINATE CHINESE MILITARY	500	Adenovirus vector recombinant vaccine	Q1(20)	Q1(21)
United States	INO-4800	PHASE 1	40	DNA vaccine with electroporation	Q2(20)	Q2(21)
Netherlands		RCT(PLAC)	1500	BCG Vaccination	Q1(20)	Q4(20)
Australia		RCT(PLAC)	4170	BCG Vaccination	Q1(20)	Q4(20)
China	CORONAVAC	PHASE I,II	743	Inactivated alum vaccine	Q2(20)	Ongoing
Russia	Gam-COVID-Vac Lyo	PHASE I		Adenovirus vector recombinant vaccine	Q2(20)	Ongoing

China	Sinopharm	PHASE I,II	1120	Inactivated virus	Q2(20)	Ongoing
Germany	Curevac	Phase I	143	mRNA Vaccine	Q2(20)	Ongoing

TABLE 5: VACCINES. The country of origin of each vaccine is listed, with name if established, the number of subjects currently being tested if known, the type of vaccine, the quarter study initiated, and the quarter and year study projects completion

(a)



(b)



Figure 1: THE PHASES OF COVID-19 INFECTION. Asymptomatic viremia typically lasts for 5 days followed by symptoms of an upper respiratory infection. The immune response takes hold over the next week. Pneumonic infiltrates begin to appear. In patients destined for severe infection, a hyperinflammatory reaction takes hold, leading to worsening of pulmonary symptoms, hypoxia, and potentially acute respiratory distress syndrome.

SUPPLEMENTARY TABLE 1: ALL TRIALS REVIEWED. SUPPLEMENTARY TABLE 1: TRIALS REVIEWED. All interventions reviewed are listed with the registration number in the listing database, the country of origin, the xeverity of illness, the clinical setting whether hospital or outpatient, they type of intervention, the number of patients projected, and the category of the intervention. CGRP: Calcitonin gene related peptide CHIMED: Traditional Chinese medication; IFN: Interferons ;LPV: Lopanovir/ritanovir; RAS: Renin angiotensin system

CLINICAL TRIAL REGISTRATION	COUNTRY	SEVERITY	SETTING	INTERVENTION	NO SUBJECTS	CLASS OF AGENT
NCT04355962	Switzerland	NA	ICU	Sevoflurane	64	ANESTHESIA
NCT04348370	United States	Non-severe	Healthcare Workers	BCG Vaccine	1800	ANGIOGENESIS INHIBITOR
NCT04305106	China	Severe	Hospital	Bevacizumab	140	ANGIOGENESIS INHIBITOR
NCT04275414	China	Severe	Hospital	Bevacizumab	20	ANGIOGENESIS INHIBITOR
IR/46977	Iran	NA	Outpatient	Minocycline	40	ANTIBIOTIC
NCT04369365	Austria	NA	Outpatient	AZT	200	ANTIBIOTIC
EU/2020-001640-26/GB/	United Kingdom	NA	ICU	Actilyse	24	ANTICOAG
NCT04365309	China	NA	Unclear	Aspirin	128	ANTICOAG
NCT04348383	Spain	Severe	Hospital	Defibrotide	120	ANTICOAG
NCT04359277	United States	NA	Hospital	Enoxaparin	1000	ANTICOAG
NCT04345848	Switzerland	NA	Hospital, ICU	Enoxaparin	200	ANTICOAG
CHI51265	China	NA	Hospital	LMW Heparin	120	ANTICOAG
NCT04368377	Italy	NA	ICU	Tirofiban, Clopidogrel, Acetylsalicylic acid, Fondaparinux	5	ANTICOAG
CHI50474	China	Unspecified	Unclear	Celecoxib	60	ANTIINFLAMMATORY
NCT04308317	China	Mixed	Unclear	Tetrandrine	60	ANTIINFLAMMATORY
CHI49738	China	Mixed	Outpatient, Hospital	Tranilast	60	ANTIINFLAMMATORY
NCT04339426	United States	NA	Unclear	Atovaquorine, AZT	25	ANTIMALARIAL
IR/47099	Iran	NA	Hospital	Chloroquine + Azithromycin + Melatonin	82	ANTIMALARIAL
NCT04333914	France	NA	Hospital	Chloroquine analog, nivolumab, TCZ	273	ANTIMALARIAL
NCT04321278	Brazil	Severe	Hospital	Azithromycin , HCQ	440	ANTIMALARIAL
NCT04324463	Canada	NA	Outpatient, Hospital	Azithromycin , HCQ	1500	ANTIMALARIAL
NCT04322396	Denmark	NA	Hospital	Azithromycin , HCQ	226	ANTIMALARIAL
EU/2020-001469-35/PL/	Poland	NA	Outpatient	Chlorine phosphate (Arechin)	400	ANTIMALARIAL
NCT04347980	France	Severe	Hospital	Dexamethasone, HCQ	122	ANTIMALARIAL
NCT04351191	Pakistan	Non-severe	Outpatient	HCQ	400	ANTIMALARIAL
NCT04351516	Germany	Mixed	Outpatient	HCQ	350	ANTIMALARIAL
NCT04346667	Pakistan	NA	Outpatient	HCQ	400	ANTIMALARIAL
NCT04362332	Netherlands	NA	Hospital	HCQ	950	ANTIMALARIAL
NCT04353037	United States	NA	Healthcare Workers,	HCQ	850	ANTIMALARIAL

NCT04354870	United States	NA	Outpatient Healthcare Workers	HCQ	350	ANTIMALARIAL
NCT04349371	United States	Non-severe	Healthcare Workers	HCQ	350	ANTIMALARIAL
IR/47090	Iran	NA	Healthy Exposed	HCQ	1000	ANTIMALARIAL
CHI49420	China	NA	Unclear	HCQ	300	ANTIMALARIAL
NCT04341441	United States	NA	Healthcare Workers	HCQ	3000	ANTIMALARIAL
NCT04308668	United States	Mixed	Healthy Exposed, Healthcare Workers, Outpatient	HCQ	3000	ANTIMALARIAL
NCT04329923	United States	Mixed	Healthcare Workers, Outpatient, Hospital	HCQ	400	ANTIMALARIAL
NCT04333654	United States	Non-severe	Outpatient	HCQ	210	ANTIMALARIAL
NCT04329611	Canada	NA	Outpatient	HCQ	1660	ANTIMALARIAL
NCT04328493	Vietnam	NA	Hospital	HCQ	250	ANTIMALARIAL
NCT04328961	United States	None	Healthy Exposed	HCQ	2000	ANTIMALARIAL
NCT04342169	United States	Non-severe	Outpatient	HCQ	400	ANTIMALARIAL
NCT04323527	Brazil	NA	Hospital	HCQ	440	ANTIMALARIAL
NCT04345692	United States	NA	Hospital	HCQ	350	ANTIMALARIAL
NCT04342650	Brazil	NA	Unclear	HCQ	210	ANTIMALARIAL
NCT04333225	United States	None	Healthcare Workers	HCQ	360	ANTIMALARIAL
NCT04342221	Germany	NA	Hospital	HCQ	220	ANTIMALARIAL
NCT04328467	United States	NA	Healthcare Workers	HCQ	3500	ANTIMALARIAL
NCT04334382	United States	Non-severe	Outpatient	HCQ	1550	ANTIMALARIAL
NCT04331834	Spain	None	Healthcare Workers	HCQ	440	ANTIMALARIAL
CHI49524	China	Mixed	Unclear	HCQ	360	ANTIMALARIAL
CHI49482	China	Severe	Hospital	HCQ	100	ANTIMALARIAL
CHI49536	China	Non-severe	Outpatient	HCQ	100	ANTIMALARIAL
CHI49607	China	NA	Unclear	HCQ	100	ANTIMALARIAL
CHI48880	China	NA	Unclear	HCQ	300	ANTIMALARIAL
EU/2020-001270-29/DK/	Denmark	Mixed	Hospital	HCQ	350	ANTIMALARIAL
NCT04318444	United States	None	Healthy Exposed	HCQ	1600	ANTIMALARIAL
NCT04315896	Mexico	Severe	Hospital	HCQ	500	ANTIMALARIAL
NCT04318015	Mexico	None	Healthcare Workers	HCQ	400	ANTIMALARIAL
NCT04316377	Norway	Mixed	Hospital	HCQ	202	ANTIMALARIAL
ISRCTNISRCTN86534580	United Kingdom	NA	Outpatient	HCQ	3000	ANTIMALARIAL
IR/46932	Iran	NA	Healthy Exposed, Healthcare Workers	HCQ	500	ANTIMALARIAL
NCT04369742	United States	NA	Hospital	HCQ	626	ANTIMALARIAL
NCT04363450	United States	NA	Healthcare Workers	HCQ	1700	ANTIMALARIAL
NCT04332991	United States	Severe	Hospital	HCQ	510	ANTIMALARIAL

NCT04334967	United States	Non-severe	Outpatient	HCQ	1250	ANTIMALARIAL
NCT04351620	United States	Non-severe	Outpatient	HCQ	20	ANTIMALARIAL
NCT04345653	United States	Non-severe	Healthcare Workers	HCQ	45	ANTIMALARIAL
CHI50843	China	NA	Hospital	HCQ	80	ANTIMALARIAL
CHI49317	China	NA	Unclear	HCQ	78	ANTIMALARIAL
CHI49218	China	Severe	Hospital	HCQ	80	ANTIMALARIAL
CHI49612	China	NA	Unclear	HCQ	100	ANTIMALARIAL
CHI48968	China	NA	Hospital	HCQ	20	ANTIMALARIAL
NCT04261517	China	NA	Unclear	HCQ	30	ANTIMALARIAL
IR/46946	Iran	NA	Healthy Unexposed	HCQ	60	ANTIMALARIAL
NCT04322123	Brazil	NA	Hospital, ICU	HCQ , Azithromycin	630	ANTIMALARIAL
IR/46536	Iran	NA	Hospital	HCQ , LPV/R , Oseltamivir	50	ANTIMALARIAL
JPJRCTS031190227	Japan	NA	Hospital	HCQ , LPV/R , Oseltamivir	50	ANTIMALARIAL
IR/47200	Iran	Moderate	Hospital	HCQ, Arbidol	40	ANTIMALARIAL
NCT04336332	United States	Non-severe	Outpatient, Hospital	HCQ, azithromycin	160	ANTIMALARIAL
NCT04335552	United States	Mixed	Hospital	HCQ, azithromycin	500	ANTIMALARIAL
NCT04344379	France	Non-severe	Healthcare Workers	HCQ, azithromycin	900	ANTIMALARIAL
NCT04329832	United States	NA	Hospital	HCQ, Azithromycin	300	ANTIMALARIAL
NCT04345861	France	NA	Hospital	HCQ, AZT	150	ANTIMALARIAL
NCT04354428	United States	NA	Outpatient	HCQ, AZT	630	ANTIMALARIAL
NCT04344444	United States	NA	Hospital	HCQ, Azt	600	ANTIMALARIAL
NCT04341727	United States	NA	Hospital	HCQ, AZT	500	ANTIMALARIAL
EU/2020-001527-14/NL/	Netherlands	NA	Hospital	HCQ, AZT	60	ANTIMALARIAL
IR/46968	Iran	NA	Hospital	HCQ, AZT, Naproxen, LPV/r, Corticosteroids	906	ANTIMALARIAL
NCT04341870	France	NA	Hospital	HCQ, AZT, Sarilumab	60	ANTIMALARIAL
NCT04370262	United States	NA	Hospital	HCQ, Famotidine	1170	ANTIMALARIAL
NCT04344457	United States	Non-severe	Outpatient	HCQ, Indomethacin, azithromycin	80	ANTIMALARIAL
NCT04344457	United States	Non-severe	Outpatient	HCQ, Indomethacin, azithromycin	80	ANTIMALARIAL
NCT04343092	Iraq	Mixed	Hospital	HCQ, Ivermectin	50	ANTIMALARIAL
IR/46926	Iran	NA	Outpatient	HCQ, LPV/r	60	ANTIMALARIAL
IR/47022	Iran	NA	Hospital	HCQ, LPV/r	100	ANTIMALARIAL
NCT04328285	France	NA	Healthcare Workers	HCQ, LPV/r,	1200	ANTIMALARIAL
IR/46561	Iran	Severe	Hospital	HCQ, LPV/r,	20	ANTIMALARIAL
IR/46814	Iran	NA	Hospital	HCQ, LPv/r, Atazanavir/r, Teicoplanin	40	ANTIMALARIAL
NCT04343768	Iran	Mixed	Hospital	HCQ, LPV/r, IFN	60	ANTIMALARIAL
IR/46790	Iran	NA	Hospital	HCQ, LPV/r, Sofosbuvir-Velpatasvir	80	ANTIMALARIAL

IR/47119	Iran	NA	Hospital	HCQ, Thalidomide	60	ANTIMALARIAL
NCT04325893	France	NA	Unclear	HCQ/placebo	1300	ANTIMALARIAL
ISRCTNISRCTN14326006	Canada	NA	Healthcare Workers	Hydroxychloroquine	988	ANTIMALARIAL
IR/46940	Iran	NA	Unclear	LPV/r, HCQ, Herbal medicine	40	ANTIMALARIAL
NCT04328012	United States	NA	Hospital	LPV/r, HCQ, losartan	4000	ANTIMALARIAL
ISRCTNISRCTN50189673	United Kingdom	Mixed	Hospital	LPV/r, IFN, HCQ, steroids	5000	ANTIMALARIAL
NCT04332094	Spain	Non-severe	Hospital	HCQ , TCZ, azithromycin	276	ANTIMALARIAL PLUS IMMUNE MODULATOR
IR/46887	Iran	Mixed	Unclear	Levamisole	50	ANTIPARASITIC
NCT04348409	Brazil	Mixed	Hospital	Nitazoxanide	50	ANTIPARASITIC
NCT04341493	Mexico	NA	Unclear	Nitazoxanide	86	ANTIPARASITIC
IR/46576	Iran	NA	Outpatient, Hospital	Noscapine	125	ANTITUSSIVE
NCT04330638	Belgium	Severe	Hospital, ICU	Anakinra, siltuximab, TCZ	342	ANTIVIRAL
NCT04339712	Greece	Severe	Unclear	Anakinra, TCZ	40	ANTIVIRAL
NCT04324489	China	Severe	Hospital	Antiviral	4	ANTIVIRAL
IR/47087	Iran	NA	Hospital	Arbidol	200	ANTIVIRAL
CHI49165	China	Non-severe	Outpatient	Arbidol	380	ANTIVIRAL
CHI49532	China	NA	Hospital	Azvudine	20	ANTIVIRAL
CHI50507	China	Mixed	Unclear	Azvudine	10	ANTIVIRAL
NCT04358614	Italy	NA	Hospital	Baricitinib	12	ANTIVIRAL
NCT04321096	Denmark	NA	Hospital	Camostat	580	ANTIVIRAL
IR/46573	Iran	Mixed	Hospital	Camostat	40	ANTIVIRAL
NCT04276688	China	NA	Hospital	Combination Antiviral	127	ANTIVIRAL
NCT04291729	China	NA	Hospital	Combination Antiviral	11	ANTIVIRAL
NCT04255017	China	NA	Unclear	Combination Antiviral	400	ANTIVIRAL
CHI50136	China	NA	Unclear	Combination Antiviral	30	ANTIVIRAL
NCT04261270	China	Mixed	Hospital	Combination Antiviral	60	ANTIVIRAL
CHI49918	China	Mixed	Hospital	Danoprevir , Ritonavir	60	ANTIVIRAL
NCT04345276	China	NA	Hospital	Danoprevir, Ritonavir	40	ANTIVIRAL
NCT04252274	China	NA	Unclear	Darunavir And Cobicistat	30	ANTIVIRAL
NCT04304053	Spain	Non-severe	Outpatient	Darunavir/Cobicistat , HCQ	3040	ANTIVIRAL
CHI49790	China	Mixed	Unclear	Ebastine	100	ANTIVIRAL
NCT04334928	Spain	Non-severe	Healthcare Workers	Emtricitabine/tenofovir, HCQ	4000	ANTIVIRAL
NCT04333589	China	NA	Unclear	Favipiravir	210	ANTIVIRAL
NCT04358549	United States	NA	Hospital	Favipiravir	50	ANTIVIRAL
CHI49988	China	NA	Unclear	Favipiravir	30	ANTIVIRAL
CHI49510	China	NA	Hospital	Favipiravir	60	ANTIVIRAL

JPJRCTS031190226	Japan	NA	Hospital	Favipiravir	50	ANTIVIRAL
JPjRCTs041190120	Japan	NA	Outpatient	Favipiravir	86	ANTIVIRAL
NCT04310228	China	NA	Unclear	Favipiravir , TCZ	150	ANTIVIRAL
CHI50137	China	NA	Hospital	Favipiravir Vs. Arbidol	240	ANTIVIRAL
IR/46942	Iran	NA	Hospital	Favipiravir, LPV/r	84	ANTIVIRAL
CHI51126	China	NA	Hospital	Favipiravir, TCZ	150	ANTIVIRAL
CHI49042	China	NA	Outpatient	Favirapir, LPV/r	90	ANTIVIRAL
JapicCTI-205238	Japan	Mixed	Hospital	FVP	96	ANTIVIRAL
NCT04319900	China	NA	Unclear	FVP, HCQ	150	ANTIVIRAL
CHI51329	China	NA	Resolved Discharged	HCQ , /- Favipiravir	150	ANTIVIRAL
IR/46897	Iran	NA	Hospital	HCQ, Arbidol, LPV/r	100	ANTIVIRAL
IR/47078	Iran	NA	Hospital	HCQ, Atazanavir/r, Vitamin C	110	ANTIVIRAL
NCT04355052	Israel	NA	Hospital	HCQ, AZT, Camostat mesilate	250	ANTIVIRAL
IR/46783	Iran	NA	Hospital	HCQ, Favipiravir, LPV/r	324	ANTIVIRAL
CHI51141	China	Non-severe	Outpatient	Interferon, ribavirin, arbidol, ribavirin	30	ANTIVIRAL
IR/47012	Iran	Unclear	Unclear	Ivermecin	100	ANTIVIRAL
CHI50251	China	Mixed	Unclear	Ixekizumab , Antiviral	40	ANTIVIRAL
CHI51112	China	NA	Unclear	Lopinavir/ritonvair	90	ANTIVIRAL
CHI48782	China	Mixed	Outpatient	LPV/r , Interferon	108	ANTIVIRAL
NCT04252885	China	NA	Unclear	LPV/r, Arbidol	125	ANTIVIRAL
NCT04275245	China	NA	Unclear	Mepaluzumab	20	ANTIVIRAL
NCT04280705	United States	Severe	Hospital	Remdesivir	800	ANTIVIRAL
NCT04292899	United States	Severe	Hospital	Remdesivir	6000	ANTIVIRAL
NCT04292730	United States	Mixed	Hospital	Remdesivir	1600	ANTIVIRAL
EU/2020-001052-18/ES/	Denmark	NA	Hospital	Remdesivir	440	ANTIVIRAL
NCT04321616	Norway	Severe	Hospital, ICU	Remdesivir, HCQ	700	ANTIVIRAL
IR/46463	Iran	Mixed	Hospital	Sofosbuvir	70	ANTIVIRAL
IR/46784	Iran	NA	Hospital	Sofosbuvir	60	ANTIVIRAL
IR/46885	Iran	NA	Hospital	Sofosbuvir + ribavirin	48	ANTIVIRAL
IR/46567	Iran	NA	Hospital	Sofosbuvir/Lepdiasvir, HCQ , Oseltamivir, LPV/r	50	ANTIVIRAL
EU/2020-001244-26/AT/	Austria	NA	ICU	Solnatide	40	ANTIVIRAL
CHI49723	China	NA	Hospital	Triazavirin	240	ANTIVIRAL
NCT04321993	Canada	Mixed	Hospital	LPV/r, HCQ, Baricitinib, Sarilumab	1000	ANTIVIRAL + IMMUNE MODULATOR
NCT04347031	Russia	NA	Hospital	Melfoquine, HCQ, AZT, TCZ	320	ANTIVIRAL + IMMUNE MODULATOR
NCT04351763	Poland	Mixed	Hospital	Amiodarone, Verapamil	804	CARDIOVASCULAR
NCT04304313	China	Mixed	Unclear	Sildenafil	10	CARDIOVASCULAR

NCT04319731	United States	NA	Hospital	Amniotic Fluid	10	CELL THERAPY
CHI51404	China	NA	Unclear	Cell Product	20	CELL THERAPY
NCT04324996	China	NA	Unclear	Engineered Cells	90	CELL THERAPY
IR/47264	Iran	NA	Hospital	Natural Killer Cells	70	CELL THERAPY
NCT04280224	China	NA	Unclear	Natural-Killer Cells	30	CELL THERAPY
NCT04361942	Spain	NA	ICU	Stem Cell	24	CELL THERAPY
NCT04339660	China	NA	Unclear	Stem Cell	30	CELL THERAPY
IR/47156	Iran	Mild/moderate	Unclear	Stem Cell Therapy	20	CELL THERAPY
NCT04349631	United States	Non-severe	Healthcare Workers	Stem Cells	56	CELL THERAPY
NCT04355728	United States	NA	Hospital, ICU	Stem Cells	24	CELL THERAPY
IR/47110	Iran	NA	ICU	Stem Cells	10	CELL THERAPY
NCT04333368	France	Severe	ICU	Stem Cells	60	CELL THERAPY
NCT04336254	China	Severe	Hospital	Stem Cells	20	CELL THERAPY
NCT04331613	China	Severe	ICU	Stem Cells	9	CELL THERAPY
CHI51904	China	Severe	Unclear	Stem Cells	36	CELL THERAPY
CHI51050	China	Severe	Hospital	Stem Cells	20	CELL THERAPY
CHI49812	China	NA	Unclear	Stem Cells	20	CELL THERAPY
CHI49901	China	Severe	Hospital	Stem Cells	16	CELL THERAPY
CHI41760	China	Severe	Hospital	Stem Cells	30	CELL THERAPY
CHI49146	China	Severe	Hospital	Stem Cells	63	CELL THERAPY
NCT04252118	China	NA	Unclear	Stem Cells	20	CELL THERAPY
NCT04288102	China	Severe	Hospital	Stem Cells	90	CELL THERAPY
NCT04313322	Jordan	NA	Unclear	Stem Cells	5	CELL THERAPY
NCT04269525	China	Severe	ICU	Stem Cells	10	CELL THERAPY
IR/46789	Iran	NA	Hospital	Stem Cells	5	CELL THERAPY
IR/47030	Iran	NA	Hospital, ICU	Stem Cells	6	CELL THERAPY
CHI49674	China	Mixed	Hospital	Stem Cells	120	CELL THERAPY
NCT04348435	United States	Non-severe	Healthcare Workers	Stem Cells	100	CELL THERAPY
CHI49254	China	Mixed	Hospital	Stem Cells	200	CELL THERAPY
NCT04367077	United States	NA	Hospital	Stem Cells	400	CELL THERAPY
NCT04346615	United States	Mixed	Hospital	Vazegepant	120	CGRP
NCT04333550	Iran	Mixed	Hospital, Unclear	Deferoxamine	50	CHELATING AGENT
CHI49631	China	Non-severe	Unclear	TCM Exercise	160	CHIMED
CHI51030	China	NA	Resolved Discharged	TCM Exercise	28	CHIMED
CHI49762	China	Non-severe	Unclear	TCM Injectable	348	CHIMED
CHI49222	China	NA	Unclear	TCM Injectable	238	CHIMED

CHI49220	China	Non-severe	Outpatient	TCM Injectable	160	CHIMED
CHI50115	China	Non-severe	Unclear	TCM Injectable	80	CHIMED
CHI50306	China	Severe	Hospital	TCM Injectable	60	CHIMED
CHI49748	China	NA	Hospital	TCM Injectable	50	CHIMED
CHI49104	China	NA	Outpatient	TCM Injectable	60	CHIMED
CHI50586	China	Mixed	Unclear	TCM Injectable	60	CHIMED
CHI49297	China	Mixed	Outpatient, Hospital	TCM Injectable	90	CHIMED
CHI50025	China	Severe	Unclear	Traditional Chinese Medicine	120	CHIMED
CHI52699	China	NA	Unclear	Traditional Chinese Medicine	200	CHIMED
CHI52477	China	NA	Unclear	Traditional Chinese Medicine	300	CHIMED
CHI52414	China	NA	Healthy Exposed	Traditional Chinese Medicine	2000	CHIMED
NCT04334265	China	Unspecified	Unclear	Traditional Chinese Medicine	750	CHIMED
CHI52106	China	NA	Unclear	Traditional Chinese Medicine	300	CHIMED
CHI51100	China	NA	Outpatient, Hospital	Traditional Chinese Medicine	2840	CHIMED
CHI51240	China	NA	Resolved Discharged	Traditional Chinese Medicine	144	CHIMED
CHI50202	China	NA	Unclear	Traditional Chinese Medicine	204	CHIMED
CHI49647	China	NA	Unclear	Traditional Chinese Medicine	132	CHIMED
CHI49543	China	Non-severe	Outpatient	Traditional Chinese Medicine	180	CHIMED
CHI49348	China	Mixed	Resolved Discharged	Traditional Chinese Medicine	100	CHIMED
CHI49408	China	NA	Hospital	Traditional Chinese Medicine	408	CHIMED
CHI49453	China	NA	Unclear	Traditional Chinese Medicine	120	CHIMED
CHI49287	China	NA	Unclear	Traditional Chinese Medicine	200	CHIMED
CHI49380	China	Severe	Hospital	Traditional Chinese Medicine	160	CHIMED
CHI48792	China	NA	Unclear	Traditional Chinese Medicine	200	CHIMED
CHI48985	China	NA	Healthy Exposed	Traditional Chinese Medicine	600	CHIMED
CHI48988	China	NA	Outpatient	Traditional Chinese Medicine	400	CHIMED
CHI49080	China	NA	Unclear	Traditional Chinese Medicine	1000	CHIMED
CHI51139	China	NA	Unclear	Traditional Chinese Medicine	400	CHIMED
CHI49051	China	NA	Unclear	Traditional Chinese Medicine	400	CHIMED
CHI48860	China	Mixed	Outpatient, Hospital	Traditional Chinese Medicine	140	CHIMED
CHI48824	China	NA	Unclear	Traditional Chinese Medicine	60	CHIMED
CHI50082	China	Mixed	Hospital	Traditional Chinese Medicine	96	CHIMED
CHI50462	China	NA	Resolved Discharged	Traditional Chinese Medicine	20	CHIMED
CHI51028	China	Non-severe	Unclear	Traditional Chinese Medicine	24	CHIMED
CHI50793	China	NA	Resolved Discharged	Traditional Chinese Medicine	120	CHIMED
CHI49014	China	NA	Unclear	Traditional Chinese Medicine	400	CHIMED

CHI49852	China	Severe	Unclear	Traditional Chinese Medicine	60	CHIMED
CHI49387	China	NA	Unclear	Traditional Chinese Medicine	30	CHIMED
CHI49490	China	Severe	Unclear	Traditional Chinese Medicine	80	CHIMED
CHI48886	China	Severe	Hospital	Traditional Chinese Medicine	42	CHIMED
IR/46775	Iran	NA	Hospital	Traditional medicine	80	CHIMED
IR/46782	Iran	NA	Hospital	Traditional medicine	68	CHIMED
NCT04251871	China	NA	Unclear	Traditional Medicine Oral	150	CHIMED
CHI48898	China	NA	Unclear	Traditional Medicine Oral	240	CHIMED
CHI48889	China	Non-severe	Unclear	Traditional Medicine Oral	240	CHIMED
CHI50476	China	NA	Resolved Discharged	Traditional Medicine Oral	100	CHIMED
CHI50986	China	Non-severe	Unclear	Traditional Medicine Oral	100	CHIMED
CHI51018	China	Non-severe	Outpatient	Traditional Medicine Oral	128	CHIMED
CHI48773	China	None	Healthy Unexposed	Traditional Medicine Oral	20000	CHIMED
CHI44213	China	Mixed	Hospital	Traditional Medicine Oral	100	CHIMED
CHI49301	China	Mixed	Hospital	Traditional Medicine Oral	120	CHIMED
CHI49138	China	Mixed	Hospital	Traditional Medicine Oral	160	CHIMED
CHI49402	China	Mixed	Outpatient, Hospital	Traditional Medicine Oral	300	CHIMED
CHI49502	China	NA	Hospital	Traditional Medicine Oral	110	CHIMED
CHI49422	China	NA	Unclear	Traditional Medicine Oral	600	CHIMED
CHI48861	China	NA	Unclear	Traditional Medicine Oral	100	CHIMED
IR/46678	Iran	Unspecified	Hospital	Traditional Medicine Oral	374	CHIMED
IR/46721	Iran	Unspecified	Outpatient	Traditional Medicine Oral	100	CHIMED
CHI50126	China	NA	Hospital	Traditional Medicine Oral	300	CHIMED
CHI48775	China	NA	Unclear	Traditional Medicine Oral	300	CHIMED
NCT04279197	China	NA	Unclear	Traditional Medicine Oral	136	CHIMED
CHI52958	China	Unclear	Unclear	Traditional medicine oral	120	CHIMED
CHI52942	China	Unclear	Unclear	Traditional medicine oral	200	CHIMED
CHI49435	China	Mixed	Unclear	Traditional Medicine Oral	40	CHIMED
NCT04347382	Pakistan	NA	Hospital	Traditional Medicine Oral	30	CHIMED
CHI49666	China	Mixed	Unclear	Traditional Medicine Oral	72	CHIMED
CHI50662	China	NA	Unclear	Traditional Medicine Oral	50	CHIMED
CHI49753	China	Mixed	Hospital	Traditional Medicine Oral	20	CHIMED
CHI49425	China	Mixed	Hospital	Traditional Medicine Oral	72	CHIMED
CHI49131	China	NA	Hospital	Traditional Medicine Oral	60	CHIMED
IR/46637	Iran	Unspecified	Hospital	Traditional Medicine Oral	60	CHIMED
IR/46715	Iran	Unspecified	Hospital	Traditional Medicine Oral	60	CHIMED

IR/47019	Iran	Unclear	Unclear	Traditional medicine oral	80	CHIMED
CHI50059	China	Severe	Hospital	Plasma Product	100	CONV PLASMA
NCT04355897	United States	NA	Hospital	Convalescent plasma	100	CONV PLASMA
NCT04362176	United States	NA	Hospital	Convalescent plasma	500	CONV PLASMA
NCT04359810	United States	NA	Hospital	Convalescent plasma	105	CONV PLASMA
NCT04357106	Mexico	NA	ICU	Convalescent plasma	10	CONV PLASMA
NCT04347681	Saudi Arabia	NA	Hospital, ICU	Convalescent plasma	40	CONV PLASMA
IR/46973	Iran	NA	Hospital	Convalescent plasma	60	CONV PLASMA
IR/47115	Iran	NA	Hospital	Convalescent plasma	30	CONV PLASMA
IR/47266	Iran	NA	ICU	Convalescent plasma	10	CONV PLASMA
CHI50537	China	Mixed	Hospital	Convalescent plasma	50	CONV PLASMA
IR/46931	Iran	NA	Hospital	Convalescent plasma	12	CONV PLASMA
IR/47212	Iran	NA	Hospital	Immunoglobulin	15	CONV PLASMA
IR/46811	Iran	NA	Hospital	Immunoglobulin	50	CONV PLASMA
IR/47014	Iran	NA	Hospital	Immunoglobulin, HCQ, LPV/r, Ribavirin	100	CONV PLASMA
NCT04342182	Netherlands	Severe	Hospital	Plasma	426	CONV PLASMA
NCT04344535	United States	Mixed	Hospital	Plasma	500	CONV PLASMA
NCT04345523	Spain	NA	Hospital	Plasma	278	CONV PLASMA
IR/46759	Iran	Severe	Hospital	Plasma	200	CONV PLASMA
NCT04364737	United States	NA	Hospital	Plasma	300	CONV PLASMA
NCT04346446	India	Severe	Hospital	Plasma	20	CONV PLASMA
NCT04343755	United States	Severe	Hospital	Plasma	55	CONV PLASMA
NCT04327349	Iran	NA	Unclear	Plasma	30	CONV PLASMA
IR/47058	Iran	NA	ICU	Plasma	32	CONV PLASMA
IR/47163	Iran	Severe	Hospital, ICU	Plasma	357	CONV PLASMA
CHI49081	China	Severe	Hospital	Plasma Product	200	CONV PLASMA
NCT04343261	United States	NA	Hospital	Plasma Product	15	CONV PLASMA
NCT04340050	United States	NA	Hospital	Plasma Product	10	CONV PLASMA
CHI51072	China	Severe	ICU	Plasma Product	10	CONV PLASMA
CHI50727	China	Severe	Hospital	Plasma Product	30	CONV PLASMA
CHI49544	China	Mixed	Outpatient, Hospital	Plasma Product	90	CONV PLASMA
CHI49861	China	Mixed	Hospital	Plasma Product	10	CONV PLASMA
CHI49533	China	NA	ICU	Plasma Product	20	CONV PLASMA
NCT04321421	Italy	Severe	ICU	Plasma Product	49	CONV PLASMA
IR/47169	Iran	NA	Unclear	Purified protein derivative	50	DIAGNOSTIC
CHI49664	China	NA	Unclear	Electrotherapy	40	ELECTROTHERAPY

IR/47015	Iran	NA	ICU	Hemodialysis	10	HEMODIALYSIS
IR/47234	Iran	NA	Outpatient	Echinacea + Ginger	100	HERBAL
NCT04322344	Italy	NA	Hospital	Escin	120	HERBAL
IR/47018	Iran	NA	Hospital	Foot bath	60	HYGIENE
NCT04344236	United States	NA	Unclear	Nasal rinses	48	HYGIENE
NCT04254874	China	Mixed	Unclear	Combination Antiviral	100	IFN
NCT04350281	China	Severe	Hospital, ICU	IFN, HCQ	80	IFN
NCT04350671	Iran	Severe	Hospital	IFN, HCQ, LPV/r,	40	IFN
CHI50470	China	NA	Unclear	Interferon Therapy	328	IFN
EU/2020-001023-14/GB/	United Kingdom	NA	Hospital	Interferon Therapy	400	IFN
NCT04331899	United States	Non-severe	Outpatient	Interferon Therapy	120	IFN
NCT04320238	China	None	Healthcare Workers	Interferon Therapy	2944	IFN
CHI49224	China	Mixed	Unclear	Interferon Therapy	100	IFN
IR/46665	Iran	Unspecified	Hospital	Interferon Therapy	40	IFN
NCT04365153	United States	NA	Hospital	Canakinumab	45	IMMUNE MODULALTOR
CHI50934	China	NA	ICU	Blood purification	20	IMMUNE MODULATOR
NCT04347226	United States	NA	Hospital	BMS-986253	138	IMMUNE MODULATOR
NCT04371367	France	NA	ICU	Avdoralimab	108	IMMUNE MODULATOR
EU/2020-001736-95/GB/	United Kingdom	Mixed	Unclear	Bemcentinib	825	IMMUNE MODULATOR
NCT04317040	United States	Severe	Hospital	Cd24f	230	IMMUNE MODULATOR
NCT04343989	United States	NA	ICU	Clazakizumab	90	IMMUNE MODULATOR
NCT04345614	United States	Severe	Hospital	CM4620	120	IMMUNE MODULATOR
NCT04328480	Argentina	Severe	Hospital	Colchicine	2500	IMMUNE MODULATOR
NCT04322682	United States	NA	Outpatient	Colchicine	6000	IMMUNE MODULATOR
NCT04360980	Iran	NA	Hospital	Colchicine	80	IMMUNE MODULATOR
NCT04363437	United States	NA	Hospital	Colchicine	70	IMMUNE MODULATOR
CHI48809	China	NA	Hospital	Cyotkine protein injection	90	IMMUNE MODULATOR
NCT04361526	Spain	NA	ICU	Cytokine Adsorption	40	IMMUNE MODULATOR
CHI49065	China	NA	Outpatient, Hospital	Cytokine Protein Injection	480	IMMUNE MODULATOR
NCT04344080	Germany	NA	ICU	Cytosorb	24	IMMUNE MODULATOR
NCT04346797	France	NA	Hospital, ICU	Eculizumab	120	IMMUNE MODULATOR
NCT04324021	Italy	Mixed	Healthcare Workers, Unclear	Emapalumab, Anakinra	54	IMMUNE MODULATOR
IR/46837	Iran	Severe	Hospital, ICU	Extracorporeal Blood Purification	10	IMMUNE MODULATOR
CHI49632	China	NA	ICU	Extracorporeal Blood Purification	60	IMMUNE MODULATOR
IR/46786	Iran	Unspecified	Hospital	Fingolimod	40	IMMUNE MODULATOR
NCT04280588	China	Mixed	Hospital	Fingolimod	30	IMMUNE MODULATOR

NCT04333420	Netherlands	Severe	Hospital	IFX-1	130	IMMUNE MODULATOR
CHI50017	China	Severe	Hospital	Jakotinib Hydrochloride	16	IMMUNE MODULATOR
NCT04351152	United States	Mixed	Hospital	Lenziulumab	238	IMMUNE MODULATOR
NCT04343651	United States	NA	Unclear	Leronimab	75	IMMUNE MODULATOR
NCT04343651	United States	NA	Unclear	Leronimab	75	IMMUNE MODULATOR
NCT04343651	United States	NA	Unclear	Leronimab	75	IMMUNE MODULATOR
NCT04347239	United States	NA	Hospital	Leronlimab	390	IMMUNE MODULATOR
NCT04342897	United States	NA	Hospital	LY3127804	200	IMMUNE MODULATOR
CHI48907	China	NA	Unclear	M1 Macrophage Suppressor	45	IMMUNE MODULATOR
NCT04334044	Mexico	NA	Unclear	Ruxolitinib	20	IMMUNE MODULATOR
NCT04338958	Germany	Severe	Hospital	Ruxolitinib	200	IMMUNE MODULATOR
NCT04326920	Belgium	Severe	Hospital	Sargramostim	80	IMMUNE MODULATOR
EU/2020-001162-12/FR/	Canada	Severe	Hospital	Sarilumab	460	IMMUNE MODULATOR
NCT04327388	Canada	Severe	Hospital	Sarilumab	300	IMMUNE MODULATOR
NCT04315298	United States	Severe	Hospital	Sarilumab	400	IMMUNE MODULATOR
NCT04359901	United States	NA	Hospital	Sarilumab	120	IMMUNE MODULATOR
NCT04357808	Spain	NA	Hospital	Sarilumab	30	IMMUNE MODULATOR
NCT04349098	United States	Severe	Hospital	Selinexor	230	IMMUNE MODULATOR
NCT04329650	Spain	Mixed	Hospital	Siltuximab	200	IMMUNE MODULATOR
NCT04348695	Spain	Mixed	Hospital	Simvastatin, ruxolitinib	94	IMMUNE MODULATOR
NCT04341675	United States	Mixed	Hospital	Sirolimus	30	IMMUNE MODULATOR
NCT04371640	United States	NA	Hospital	Sirolimus	40	IMMUNE MODULATOR
NCT04322773	Denmark	Severe	Hospital	TCZ	200	IMMUNE MODULATOR
GERDRKS00021238	Germany	NA	ICU	TCZ	200	IMMUNE MODULATOR
NCT04335071	Switzerland	Severe	Hospital	TCZ	100	IMMUNE MODULATOR
CHI49409	China	Mixed	Hospital	TCZ	188	IMMUNE MODULATOR
NCT04320615	United States	Severe	Hospital	TCZ	330	IMMUNE MODULATOR
NCT04317092	Italy	Severe	Hospital	TCZ	400	IMMUNE MODULATOR
NCT04361552	United States	NA	Hospital	TCZ	180	IMMUNE MODULATOR
NCT04363853	Mexico	Severe	Hospital, ICU	TCZ	200	IMMUNE MODULATOR
NCT04331795	United States	NA	Hospital	TCZ	50	IMMUNE MODULATOR
NCT04346355	Italy	Mixed	Hospital	TCZ	398	IMMUNE MODULATOR
IR/47021	Iran	NA	ICU	TCZ	10	IMMUNE MODULATOR
NL8504	Netherlands	NA	Hospital	TCZ	354	IMMUNE MODULATOR
EU/2020-001770-30/BE/	Belgium	Severe	Hospital	TCZ	60	IMMUNE MODULATOR
CHI50693	China	Severe	Hospital	TCZ , Adalimumab	60	IMMUNE MODULATOR

NCT04335305	Spain	Severe	Hospital	TCZ, pembrolizumab	24	IMMUNE MODULATOR
CHI49161	China	Severe	Hospital	Thymosin	120	IMMUNE MODULATOR
NCT04341116	United States	Severe	Hospital	TJ003234	144	IMMUNE MODULATOR
CHI49215	China	NA	Hospital	vMIP	40	IMMUNE MODULATOR
NCT04350580	France	Severe	ICU	Immunoglobulin	138	IVIG
IR/47219	Iran	Severe	Hospital, ICU	IVIG, LPV/r	20	IVIG
CHI49075	China	Mixed	Hospital	Asc09/Ritonavir	160	LPV
CHI49514	China	Mixed	Outpatient, Hospital, ICU	Carriomycin	520	LPV
CHI49263	China	NA	Outpatient	HCQ, LPV/r	112	LPV
NCT04364022	Switzerland	NA	Healthy Exposed	HCQ, LPV/r	420	LPV
CHI48684	China	NA	Hospital	LPV/r	160	LPV
CHI48991	China	NA	Outpatient	LPV/r	328	LPV
NCT04330690	Canada	Mixed	Hospital	LPV/r	440	LPV
NCT04321174	Canada	None	Healthy Exposed	LPV/r	1220	LPV
NCT04307693	South Korea	Non-severe	Outpatient	LPV/r	150	LPV
CHI50057	China	NA	Unclear	LPV/r	60	LPV
NCT04365127	United States	NA	Hospital	Progesterone	40	MATABOLIC
NCT04365699	United States	NA	Hospital	AT-001	500	METABOLIC
IR/46639	Iran	NA	Hospital	Atorvastatin	100	METABOLIC
NCT04350593	United States	Mixed	Hospital	Dapagliflozin	900	METABOLIC
NCT04359329	United States	NA	Outpatient	Estradiol	110	METABOLIC
IR/46762	Iran	NA	Outpatient	Medium-chain triglyceride	120	METABOLIC
IR/46690	Iran	Mixed	Hospital	Metformin	200	METABOLIC
IR/47334	Iran	NA	Hospital	Sitagliptin	84	METABOLIC
IR/47141	Iran	Unclear	Outpatient	Lithium	40	MINERAL
IR/47244	Iran	Unclear	Hospital	Azithromycin + Oseltamivir + LPV/r + Atazanavir + Hydroxychloroquine	110	MULTITHERAPY
IR/46538	Iran	NA	Hospital	HCQ , Oseltamivir , LPV/r , IFN	30	MULTITHERAPY
NCT04366089	Italy	NA	Hospital	HCQ, Azithromycin, Oxygen, Probiotic, Dietary supplement	152	MULTITHERAPY
IR/46810	Iran	NA	Hospital	HCQ, Corticosteroids, Interferon, Immunoglobulin	105	MULTITHERAPY
IR/46853	Iran	NA	Hospital	HCQ, Sof+Dac, Lithium, Trifluoprazine + trihexyphenidyl	80	MULTITHERAPY
NCT04331470	Iran	NA	Unclear	Levamisole, LPV/r, HCQ	30	MULTITHERAPY
NCT04350684	Iran	Mixed	Hospital	IFN, HCQ, LPV/R, Umifenovir	40	MULTITHERAPY
IR/46681	Iran	Mixed	Hospital	TCZ, LPV/r, HCQ, oseltamivir	40	MULTITHERAPY
IR/47052	Iran	Unclear	Unclear	LPV/r, Naproxen, HCQ, Oseltamivir	101	MULTITHERAPY
IR/46533	Iran	NA	Unclear	Pirfenidone, Chloroquine, LPV/r, Oseltamivir	40	MULTITHERAPY
NCT04366245	Spain	NA	Hospital	Plasma, HCQ, LPV/r, Azithromycin	72	MULTITHERAPY

NCT04315948	France	Severe	Hospital	Remdesivir, LPV/r, Interferon, HCQ	3100	MULTITHERAPY
CHI49088	China	Severe	Hospital	Stem Cell, Ruxolitinib	70	MULTITHERAPY
NCT04326426	United States	Severe	Hospital	Tradipitant	300	NEURO
NCT04343963	Mexico	NA	Hospital	Pyridostigmine Bromide	436	NEUROGENIC
NCT04368156	Spain	NA	Hospital	Vagus nerve stimulation	90	NEUROGENIC
NCT04346693	Russia	NA	Hospital	Dalargin	320	OPIOID
CHI49342	China	Non-severe	Unclear	Polyinosinic- Polycytidylic Acid	40	POLYNUCLEOTID
NL8491	Netherlands	Severe	Hospital	Imatinib	386	PROTEIN KINASE INHIBITOR
EU/2020-001236-10/NL/	Netherlands	Severe	Hospital	Imatinib mesilate	304	PROTEIN KINASE INHIBITOR
CHI49952	China	NA	Outpatient	Psychological	180	PSYCHOLOGIC
NCT04342663	United States	NA	Outpatient	Fluvoxamine	152	PSYCHOLOGIC
IR/47006	Iran	NA	Hospital	Trifluoperazine, HCQ	70	PSYCHOLOGIC
NCT04326452	United States	Severe	Hospital	Bidirectional oxygen	15	PULMONARY
IR/46969	Iran	NA	Hospital	Bromhexine	60	PULMONARY
NCT04355364	France	NA	ICU	Dornase Alfa Inhalation Solution	100	PULMONARY
CHI50910	China	Severe	ICU	ECMO	30	PULMONARY
GERDRKS00021300	Germany	Severe	Hospital	Ecmo	30	PULMONARY
IR/47173	Iran	Unclear	Unclear	Formoterol	50	PULMONARY
NCT04325906	United States	Severe	ICU	High nasal flow cannula	346	PULMONARY
EU/2020-001391-15/IE/	Ireland	NA	Hospital	HUMAN ALPHA1-PROTEINASE INHIBITOR	36	PULMONARY
NCT04332081	United States	NA	Hospital	Hyperbaric oxygen	40	PULMONARY
CHI49799	China	NA	Unclear	Inhaled solution	60	PULMONARY
NCT04340414	China	NA	Hospital	Low flow ECMO	10	PULMONARY
NCT04359251	China	NA	Hospital	Mechanical Support	20	PULMONARY
NCT04344730	France	NA	ICU	O2 support, Corticosteroids	550	PULMONARY
NCT04359862	Spain	NA	Hospital, Unclear	Sedation	50	PULMONARY
NCT04359862	Spain	NA	Hospital, Unclear	Sedation	50	PULMONARY
NCT04355026	Slovenia	NA	Hospital	HCQ, Bromhexine	90	PULMONARY
NCT04336462	China	Severe	Hospital	Hydrogen , oxygen	100	PULMONARY
NCT04344431	France	NA	Hospital	Hyperbaric oxygen	100	PULMONARY
EU/2020-001329-30/AT/	China	NA	ICU	Nitric oxide	200	PULMONARY
NCT04305457	United States	Mixed	Hospital	Nitric Oxide	240	PULMONARY
NCT04306393	United States	Severe	ICU	Nitric Oxide	200	PULMONARY
CHI49283	China	Mixed	Hospital	Oxygen	440	PULMONARY
NCT04320056	Canada	Severe	Hospital	Oxygen	216	PULMONARY
CHI49747	China	Mixed	Outpatient, Hospital	Ozone	180	PULMONARY

CHI49947	China	Mixed	Outpatient, Hospital	Ozone	60	PULMONARY
CHI49737	China	NA	Hospital	Ozone	60	PULMONARY
IR/47149	Iran	NA	Unclear	Ozone Major Autohemotherapy	80	PULMONARY
NCT04359797	United States	NA	Hospital	Prone positioning	300	PULMONARY
NCT04358939	France	NA	Hospital	Prone positioning	248	PULMONARY
NCT04344106	France	NA	Hospital, ICU	Prone positioning	25	PULMONARY
NCT04337541	Denmark	Non-severe	Healthcare Workers, Outpatient	Surgical facial mask	6000	PULMONARY
NCT04331366	United States	Mixed	Hospital	Bidirectional oxygen	5	PULMONARY
CHI48801	China	Severe	Hospital, ICU	Pirfenidone	292	PULMONARY FIBROSIS RX
NCT04282902	China	NA	Hospital	Pirfenidone	294	PULMONARY FIBROSIS RX
CHI51416	China	NA	Unclear	Pirfenidone	40	PULMONARY FIBROSIS RX
CHI51118	China	NA	Unclear	Pirfenidone	40	PULMONARY FIBROSIS RX
NCT04366791	United States	NA	Hospital	Radiation	10	RADIATION
NCT04330300	Ireland	NA	Healthy Unexposed	Antihypertensives	2414	RAS
NCT04364893	Brazil	NA	Hospital	ARB and ACEi	500	RAS
NCT04329195	France	NA	Hospital	Discontinuation of RAS	554	RAS
NCT04340557	United States	NA	Hospital	Losartan	200	RAS
IR/46824	Iran	Unspecified	Hospital	Losartan	100	RAS
NCT04312009	United States	Severe	Hospital	Losartan	200	RAS
NCT04311177	United States	Non-severe	Outpatient	Losartan	580	RAS
NCT04335123	United States	Severe	Hospital, ICU	Losartan	50	RAS
NCT04355936	Argentina	NA	Unclear	Telmisartan	400	RAS
NCT04335786	Netherlands	Mixed	Hospital	Valsartan	651	RAS
CHI50341	China	NA	Unclear	Physical rehabiliation	80	REHABILITATION
NCT04365738	Turkey	NA	Outpatient	Respiratory coaching	270	REHABILITATION
CHI50973	China	Severe	Hospital	Statin	100	SERINE PROTEASE INHIBITOR
ISRCTNISRCTN83971151	Argentina	NA	Hospital	LPV/r, IFN, HCQ, remdesivir	10000	SOLIDARITY
JPjRCTs031190269	Japan	Unspecified	Outpatient	Ciclesonide	100	STEROID
NCT04348305	Denmark	Severe	Hospital, ICU	Corticosteroids	1000	STEROID
NCT04355637	Spain	NA	Hospital	Corticosteroids	300	STEROID
NCT04343729	Brazil	NA	Unclear	Corticosteroids	420	STEROID
NCT04331054	France	NA	Hospital	Corticosteroids	436	STEROID
NCT04327401	Brazil	Mixed	Unclear	Corticosteroids	290	STEROID
CHI50453	China	NA	Outpatient, Hospital	Corticosteroids	200	STEROID
NCT04263402	China	Severe	Unclear	Corticosteroids	100	STEROID
NCT04344288	France	NA	Hospital	Corticosteroids	304	STEROID

IR/46904	Iran	NA	Hospital	Methylprednisolone	40	STEROID
IR/47088	Iran	NA	ICU	Methylprednisolone	40	STEROID
NCT04325061	Spain	Severe	Hospital	Corticosteroids	200	STEROIDS
IR/46776	Iran	NA	Hospital	Corticosteroids	48	STEROIDS
NCT04355247	Puerto Rico	NA	Hospital	Corticosteroids	20	STEROIDS
CHI48777	China	Severe	Hospital	Corticosteroids	48	STEROIDS
NCT04244591	China	Severe	ICU	Corticosteroids	80	STEROIDS
NCT04323592	Italy	Severe	Hospital	Corticosteroids	104	STEROIDS
NCT04341038	Spain	Severe	ICU	Corticosteroids, tacrolimus	84	STEROIDS
CHI49534	China	Severe	Hospital	Alpha Lipoic Acid	68	SUPPLEMENT
IR/47139	Iran	NA	Outpatient	Asafoetdida	60	SUPPLEMENT
IR/46868	Iran	NA	Outpatient	Berberine	40	SUPPLEMENT
IR/47193	Iran	NA	Hospital	Black myrobalan + Mastic + Sugarcane	10	SUPPLEMENT
IR/46875	Iran	NA	Hospital	Calcifediol	260	SUPPLEMENT
IR/47010	Iran	NA	Healthy Exposed, Healthcare Workers	Calcifediol	540	SUPPLEMENT
IR/46978	Iran	NA	Outpatient	Crocetin	40	SUPPLEMENT
IR/46554	Iran	NA	Hospital	Crostop/Croguard	150	SUPPLEMENT
IR/46879	Iran	NA	Hospital	Herbal	110	SUPPLEMENT
IR/46913	Iran	NA	Unclear	Herbal	130	SUPPLEMENT
IR/46828	Iran	NA	Hospital	Herbal	60	SUPPLEMENT
IR/46850	Iran	NA	Unclear	Herbal	60	SUPPLEMENT
IR/46907	Iran	NA	Unclear	Herbal	60	SUPPLEMENT
IR/46958	Iran	NA	Outpatient	Herbal	40	SUPPLEMENT
IR/46961	Iran	NA	Hospital	Herbal	15	SUPPLEMENT
IR/47016	Iran	NA	Hospital	Herbal	60	SUPPLEMENT
IR/46733	Iran	NA	Hospital	Herbal medicine	64	SUPPLEMENT
IR/46893	Iran	NA	Outpatient	Licorice	40	SUPPLEMENT
CHI50421	China	Mixed	Outpatient, Hospital	Lipoic Acid	394	SUPPLEMENT
IR/46903	Iran	NA	Hospital	Marshmallow + Licorice	60	SUPPLEMENT
IR/46963	Iran	NA	ICU	Melatonin, Vitamin C	20	SUPPLEMENT
NCT04323345	Egypt	NA	Unclear	Nutritional Support	1000	SUPPLEMENT
NCT04323514	Italy	Severe	Hospital	Nutritional Support	500	SUPPLEMENT
IR/47251	Iran	NA	Hospital	Pomegranate syrup	66	SUPPLEMENT
NCT04366180	Spain	NA	Healthcare Workers	Probiotic	314	SUPPLEMENT
CHI49321	China	Mixed	Outpatient, Hospital	Probiotics	300	SUPPLEMENT
CHI49530	China	Severe	Hospital	Regulating Intestinal Flora Agent	60	SUPPLEMENT

IR/47318	Iran	NA	Hospital	Syrup zofa	100	SUPPLEMENT
IR/46974	Iran	NA	Unclear	Vitamin A	140	SUPPLEMENT
NCT04264533	China	Severe	ICU	Vitamin C	140	SUPPLEMENT
NCT04357782	United States	NA	Hospital	Vitamin C	20	SUPPLEMENT
IR/46804	Iran	NA	Hospital	Vitamin C	60	SUPPLEMENT
NCT04342728	United States	Non-severe	Outpatient	Vitamin C, Zinc	520	SUPPLEMENT
NCT04344041	France	NA	Unclear	Vitamin D	260	SUPPLEMENT
IR/46751	Iran	Unspecified	Hospital	Vitaminc C	40	SUPPLEMENT
IR/46838	Iran	NA	ICU	Vitamins	60	SUPPLEMENT
NCT04328441	Netherlands	NA	Healthcare Workers	BCG Vaccine	1500	VACCINE
NCT04327206	Australia	NA	Healthcare Workers	BCG Vaccine	4170	VACCINE
NCT04352608	China	NA	Healthy Unexposed	Vaccine	744	VACCINE
EU/2020-001072-15/GB/	United Kingdom	NA	Healthy Unexposed	Vaccine	510	VACCINE
NCT04283461	United States	None	Healthy Unexposed	Vaccine	105	VACCINE
NCT04324606	United Kingdom	None	Healthy Unexposed	Vaccine	1112	VACCINE
NCT04276896	China	NA	Hospital	Vaccine	100	VACCINE
NCT04299724	China	NA	Healthy Unexposed, Healthy Exposed, Outpatient	Vaccine	100	VACCINE
CURPCEC00000306-En	Cuba	NA	Healthy Exposed	Vaccine	80	VACCINE
NCT04336410	United States	Non-severe	Healthy Unexposed	Vaccine	40	VACCINE
NCT04336410	United States	Non-severe	Healthy Unexposed	Vaccine	40	VACCINE

SUPPLEMENTARY TABLE 2: OTHER AGENTS. The interventions are listed by class. The setting of each study, whether hospital or outpatient, the type of control (AC: Active control, RCT: randomized control; soc: standard of care; PLAC: placebo control, whether treatment (TREAT) or prevention (PREV), the severity of illness, number of subjects, quarter study initiated, quarter study projects completion of enrollment, and duration of symptoms for patient inclusion are listed. Studies projecting completion of enrollment by the end of the second quarter of 2020 are bolded. Outpatient studies with planned completion by the end of the second quarter of 2020 are italicized.

TREATMENT	TYPE OF CONTROL	TREAT OR PREVENT	SEVERITY	NUMBER SUBJECTS	BEGIN DATE	PROPOSED END ENROLLMENT	DURATION SYMPTOMS
			IMMUNE GLOBULIN				
CONVALESCENT PLASMA	RCT PLAC	TREAT	MIXED	500	Q2(20)	Q2(21)	14
	RCT (soc)	TREAT	MIXED	426	Q2(20)	Q3 (20)	4
	RCT (soc)	TREAT	MIXED	278	Q2(20)	Q3 (20)	12
	RCT (soc)	TREAT	SEV	200	Q1(20)	Q1(21)	3
	RCT (soc)	TREAT	SEV,CRIT	100	Q1(20)	**Q2(20)**	ANY DUR
IVIG	RCT (PLAC)	TREAT	SEV,CRIT	138	Q2(20)	Q3 (20)	ANY DUR
			CELL THERAPY				
STEM CELL	RCT(PLAC)	PREV	HEALTHY	100	Q2(20)	Q4(20)	N/A
	Case control	TREAT	MIXED	200	Q1(20)	Q4(21)	ANY DUR
	RCT(PLAC)	TREAT	SEV	120	Q1(20)	Q2(20)	ANY DUR
			CARDIOVASCULAR				
DISCONTINUATION OF RAS	AC (continue or discontinue RAS)	TREAT(2) PREV(1)	MIXED, HEALTHY	554;500;2414	Q2(20),Q1(20)	Q3 (20);Q4(20);Q1(21)	ANY DUR, N/A
LOSARTAN	RCT (soc)	TREAT	MIXED	100	COMPLETED		
	RCT (soc)	TREAT	MILD,MOD	200	Q2(20)	Q3 (20)	ANY DUR
	RCT (soc)	TREAT	MILD,MOD	580	Q2(20)	Q2(21)	3
	RCT (soc)	TREAT	SEV,CRIT	200	Q2(20)	Q2(21)	ANY DUR
TELMISARTAN	RCT(soc)	TREAT	MIXED	400	Q2(20)	Q3 (20)	ANY DUR
VALSARTAN	RCT (PLAC)	TREAT	MOD	651	Q2(20)	Q3 (20)	1

AMIODARONE	AC(verapamil)	TREAT	MIXED	804	Q2(20)	Q1(21)	ANY DUR
			PULMONARY TREATMENT				
PIRFENIDONE	RCT (soc)	TREAT	MIXED	294	Q1(20)	**Q2(20)**	7
	RCT (soc)	TREAT	SEV,CRIT	292	Q1(20)	Q3(20)	14
HYPERBARIC OXYGEN	RCT (soc)	TREAT	MIXED	100	Q2(20)	Q2(21)	ANY DUR
INHALED NITRIC OXIDE	RCT(soc)	TREAT	MIXED	240	Q1(20)	Q2(21)	ANY DUR
	RCT(soc)	TREAT	SEV,CRIT	200	Q1(20)	Q2(21)	ANY DUR
DORNASE ALFA (cystic fibrosis agent)	RCT (soc)	TREAT	CRIT	100	Q2(20)	Q4(20)	ANY DUR
PRONE POSITION	AC(supine)	TREAT(2)	CRIT; MIXED	248;300	Q2(20)	Q4(20); Q1(21)	ANY DUR
OZONE	RCT (soc)	TREAT	MIXED	180	Q1(20)	**Q2 (20)**	7
OXYGEN/HYDROGEN	AC (oxygen)	TREAT(2)	MOD,SEV	100;440	Q1(20)	Q3 (20)	ANY DUR
SURGICAL FACE MASK	AC(face mask or none)	PREV	HEALTHY	6000	Q2(20)	Q3 (20)	N/A
CLOSED LOOP OXYGEN	AC (normal O2 delivery vs closed loop)	TREAT	MOD,SEV	216	Q2(20)	Q4(20)	ANY DUR
RESPIRATORY COACHING	RCT (soc)	TREAT	MILD,MOD	270	Q1(20)	Q3 (20)	ANY DUR
			ONCOLOGIC AGENTS				
IMATINIB	RCT (PLAC)	TREAT(2)	SEV	304;386	Q1(20)	**Q2 (20)**	ANY DUR
LY3127804	RCT (PLAC)	TREAT	MIXED	200	Q2(20)	Q3 (20)	ANY DUR
BEVACIZUMAB	RCT (soc)	TREAT	SEV,CRIT	140	Q1(20)	**Q2(20)**	ANY DUR
			METABOLIC AGENTS				

METFORMIN	RCT (soc)	TREAT	MIXED	200	Q1(20)	**Q2 (20)**	ANY DUR
DAPLIGLIFLOZIN	RCT (PLAC)	TREAT	MILD,MOD	900	Q2(20)	Q4(20)	3
ESTRADIOL	RCT (soc)	TREAT	MILD,MOD	110	Q2(20)	Q4(20)	7
ATORVASTATIN	RCT (soc)	TREAT	MIXED	100	Q2(20)	NO DATE	ANY DUR
MEDIUM CHAIN TG	RCT (soc)	TREAT	MILD	120	Q2(20)	*Q2 (20)*	ANY DUR
			SUPPLEMENTS				
ECHINACEA AND GINGER	RCT (soc)	TREAT	MILD	100	Q2(20)	***Q2 (20)***	ANY DUR
VITAMIN D	AC (200,000 IU vs 50,000 IU), RCT(soc)	TREAT(3)	MILD,MOD	260;260;540	Q2(20)	Q3 (20), Q4(20)	3, ANY DUR
ASCORBIC ACID	RCT (PLAC)	TREAT	CRIT	140	Q1(20)	Q3 (20)	ANY DUR
ASCORBIC ACID, ZINC	AC(ascorbic acid, zinc, soc)	TREAT	MILD	520	Q2(20)	Q3 (20)	ANY DUR
LIPOIC ACID	RCT (soc)	TREAT	MIXED	394	Q1(20)	***Q2 (20)***	ANY DUR
PROBIOTICS	RCT (soc);RCT(PLAC)	TREAT;PREV	MIXED;HEALTHY	300;314	Q1(20);Q2(20)	Q3 (20)	ANY DUR
NATURAL HONEY	RCT (soc)	TREAT	MIXED	1000	Q1(20)	Q4(20)	ANY DUR
ESCIN	RCT (soc)	TREAT	MIXED	120	Q1(20)	**Q2 (20)**	ANY DUR
Crostop/Croguard	RCT (soc)	TREAT	MIXED	150	Q1(20)	**Q2 (20)**	ANY DUR
VITAMIN A	RCT (soc)	TREAT	MIXED	140	Q2(20)	NO DATE	ANY DUR
			NEUROGENIC				
TRADIPITANT	RCT (PLAC)	TREAT	SEV,CRIT	300	Q2(20)	Q3 (20)	ANY DUR

PYRIDOSTIGMINE	RCT (PLAC)	TREAT	SEV	436	Q2(20)	Q2(21)	ANY DUR
VAZEGEPANT	RCT (PLAC)	TREAT	SEV	120	Q2(20)	Q3 (20)	ANY DUR
			PSYCHOLOGICAL				
FLUVOXAMINE	RCT (PLAC)	TREAT	MILD	152	Q2(20)	Q3 (20)	ANY DUR
PSYCHOLOGICAL THERAPY	RCT (soc)	TREAT	MIXED	180	Q1(20)	Q1(22)	ANY DUR
			GLUCOCORTICOIDS				
METHYLPREDNISOLONE	AC (high vs low dose)	TREAT	SEV	100	Q1(20)	Q2 (20)	ANY DUR
CORTICOSTEROID	AC (early vs late vs no steroid)	TREAT	MIXED	200	Q1(20)	Q2 (20)	ANY DUR
DEXAMETHASONE	RCT (soc)	TREAT(2)	CRIT	290;200	Q2(20)	Q3 (20),Q4(20)	1,ANY DUR
CICLESONIDE	RCT (PLAC)	TREAT	SEV	120	Q2(20)	Q3 (20)	ANY DUR
SYMBICORT	RCT (soc)	TREAT	MIXED	436	Q2(20)	Q3 (20)	2
			ANTICOAGULATION				
ASPIRIN	RCT (soc)	TREAT	MIXED	128	Q1(20)	Q2 (20)	ANY DUR
LOW MOLECULAR WEIGHT HEPARIN	AC(lmw vs mechanical VTE prev)	PREV	MIXED	120	Q1(20)	Q2 (20)	ANY DUR
DEFIBROTIDE	RCT (PLAC)	TREAT	SEV,CRIT	120	Q2(20)	Q3 (20)	ANY DUR
ULINASTATIN	RCT (soc)	TREAT	MIXED	100	Q1(20)	Q2 (20)	ANY DUR